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1. Zusammenfassung / Summary 
1.1 Zusammenfassung 
Das humane Immundefizienzvirus (HIV) weist eine hohe genetische 
Variabilität auf, besitzt aber einen sehr stabilen Phänotyp. Sowohl die hohen 
Mutations- und Rekombinationsraten, als auch die Fähigkeit zur 
Mehrfachinfektion von Einzelzellen tragen zur Variabilität bei. Diese 
ermöglicht es HIV, der Inhibition z.B. durch antivirale Medikamente zu 
entgehen. Da Mutationen allerdings vor allem eine nachteilige Wirkung auf 
das Virus haben, muss HIV eine Balance zwischen Replikationsfehlern und 
Funktionalität bewahren. Dies könnte zum einen durch Fitnessinteraktionen 
zwischen Mutationen, zum anderen durch phänotypische Mischung 
geschehen. Durch eine hoch auflösende Fitnessanalyse entlang eines 
wichtigen HIV-Resistenzentwicklungspfades sowie durch die Quantifizierung 
des Einflusses der Epistase auf Mutationshäufigkeit und das Ausmaß der 
phänotpyischen Mischung, bietet die vorliegende Doktorarbeit neue 
Einsichten in beide Phänomene.  
 
Die Muster der epistatischen Interaktionen zwischen den einzelnen 
Mutationen sind komplex und abhängig von Faktoren wie die An- oder 
Abwesenheit von antiviraler Medikation oder dem zu infizierenden Zelltyp. 
Abhängig von diesen Parametern können einige der Interaktionen einen 
Verlust an Fitness kompensieren und die Epistase kann einen großen 
Einfluss auf die relativen Mutantenhäufigkeiten haben. In anderen Fällen war 
der beobachtete Effekt gering. Bedenkt man die starke Abhängigkeit 
gegenüber diesen unterschiedlichen Faktoren, so scheint die Epistase als 
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genereller Mechanismus der Abpufferung von Fitnessverlusten eine 
ineffiziente Robustness-Strategie zu sein. Die Fitness und Infizierbarkeit der 
phänotypisch-gemischten Varianten sank mischungsabhängig von den 
reinen Phänotypen her ab. Daraus lässt sich schließen, dass die 
Genprodukte der Mutationen im Virion keinen drastischen Einfluss auf den 
resultierenden Phänotyp haben. Dies führt zu der Annahme, dass die 
phänotypische Mischung in vivo zur HIV-Robustheit beitragen kann. Um dies 
weiter zu untersuchen werden die Fitness- und Infektionwerte, die im Zuge 
dieser Arbeit bestimmt wurden, in ein mathematisches Modell zur HIV-
Evolution eingegeben. Dies wird zu einem besseren quantitativen 
Verständnis der Konsequenzen von HIV-Multiinfektonen führen. 
 
1.2 Summary 
The human immunodeficiency virus (HIV) has an extraordinary genetic 
diversity but a remarkably robust phenotype. High mutation and 
recombination rates plus its ability to multinfect single-cells contribute to this 
diversity and allow HIV to evade selection pressures such as antiviral drug 
treatments and vaccines. Because mutations are usually deleterious, HIV 
has to keep a balance between replication errors and functionality. This may 
be exerted by fitness interactions between mutations and phenotypic mixing. 
This thesis work provides new insights into these two phenomena by high-
resolution fitness analysis along an important HIV drug-resistance mutation 
pathway and quantifying the impact of epistasis on mutant frequencies and 
the size of the phenotypic mixing effect. The pattern of epistatic interactions 
between the specific mutations is complex and dependent on environmental 
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factors such as the presence and absence of drugs and the host cells used. 
Depending on those conditions some interactions can compensate fitness 
losses and epistasis can have a large effect on the relative mutant 
frequencies while in other cases the effect was small. Given the strong 
dependency on such environmental factors, epistasis as a general buffering 
mechanism for fitness losses might be rather inefficient. Overall, the fitness 
and infectivity of the phenotypically mixed variants decreased gradually 
between the pure phenotypes in a ratio-dependent manner, suggesting that 
the incorporation of certain mutant products inside the virions does not 
change drastically the function of the resulting phenotype. This supports the 
notion that phenotypic mixing might contribute as a strategy of viral 
robustness in vivo. To further address this issue, the fitness and infectivity 
values generated from the experiments performed during this thesis work will 
be feed into a complete mathematical model of HIV evolution. This will help 
to better understand the consequences of multinfection in HIV in quantitative 
terms. 
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2. Introduction 
2.1 HIV causes AIDS  
The Human Immunodeficiency Virus (HIV) is one of the most important 
human pathogens. HIV causes Acquired Immune Deficiency Syndrome 
(AIDS) of the host by progressively destroying CD4+ T helper cells (Norris 
and Rosenberg 2002), as well as causing oncological and neurological 
diseases (Salami, Ogunmodele et al. 2009; Saloura, Grivas et al. 2009).  
 
AIDS was first described in 1981 in homosexual men suffering from 
abnormal opportunistic infections (Gottlieb, Schroff et al. 1981). The 
ethiological agent was isolated in 1983 from the lymph node of a patient with 
immune failure and it was called Lymphadenopathy Associated Virus (Barre-
Sinoussi, Chermann et al. 1983). In 1986 the virus was renamed HIV (Coffin, 
Haase et al. 1986). 
 
Today, the infection has become a worldwide epidemic with estimates of 
around 30 to 36 million infected people, the majority of them living in the Sub-
Saharan region of Africa (WHO Report, UNAIDS/09.36E/JC1700E) (Figure 
1). Despite the more than 30 years of research, there is still no effective 
vaccine and current anti-viral therapies fail to eradicate the virus from the 
infected host. Therefore, and even when prevention programs are showing 
signs of success, HIV continues to be a major health concern worldwide.  
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Figure 1. Adults and children estimated to be living with HIV, end of 2008.  (Adapted from 
WHO Report, UNAIDS/09.36E/JC1700E) 
 
2.1.1 Structure of HIV-1 
The HIV Type 1 and Type 2 are classified as lentiviruses belonging to the 
family Retroviridae (Tang, Kuhen et al. 1999). The infectious particles show a 
spherical structure with a diameter of about 100 nm (Figure 2A). The viral 
membrane is build by the host cell cytoplasmic membrane in association with 
viral envelope proteins. The matrix proteins (MA) are connected with the viral 
membrane by amino terminal myristyl acids forming an isometric structure 
(Figure 2B). The viral genome is carried inside the capsid formed by p24, 
one of the group specific antigen proteins (Gag). The genome is also 
associated with the nucleocapsid proteins (NC). The capsid is connected to 
the virion core by the p6 protein and contains the enzymatic proteins reverse 
transcriptase (RT), integrase (IN) and protease (PR) (Figure 2B). 
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Figure 2. The HIV particle. A) Electron microscopy picture of HIV virions emerging from a 
host cell. B) Schematic representation of the HIV virion showing its most important 
components. 
 
The HIV-1 genome is around 10 kb in size, and is encoded by two copies of 
single-stranded RNA consisting of a 5`cap structure and a 3´ polyadenylation 
B 
A 
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signal. Figure 3 shows a schematic summary of the genome, transcripts and 
proteins of HIV. The genome encodes for proteins Gag (group specific 
antigens), Pol (enzymatic activities), Env (envelope glycoproteins) and 
additional regulatory and accessory proteins (Frankel and Young 1998). The 
coding regions are flanked by regulatory control sequences termed long 
terminal repeats (LTR) (Coffin 1979). These repetitive sequences consist of 
three different regions termed U5 (unique), R (repeated) and U3 (unique), 
which are located at the 5´end and the 3´end in the provirus genome. The 
LTR bears all cis-active sequences as well as elements of the promoter and 
enhancer sequences controlling viral gene expression. In addition, both LTRs 
are essential for the process of reverse transcription and integration of the 
viral DNA into the host cell genome (Nisole and Saib 2004).  
 
The retroviral gag gene encodes for a precursor protein of 55 kDa 
synthesized on ribosomes in the cytoplasm of the host cell. During 
maturation of the virus, gag is processed by the viral protease into the matrix 
protein (MA), the capsid protein (p24), the nucleocapsid protein (NC) and p6 
(Ganser-Pornillos, Yeager et al. 2008). The NC protein forms together with 
the viral RNA a ribonucleo-protein complex by the interaction with a leader 
sequence termed ψ-region on the RNA genome. By this mechanism it 
supports the assembly of the RNA genome and the tLys-RNA primer to 
initiate the reverse transcription of the genomic RNA (Nisole and Saib 2004). 
The pol genes, encoding for the viral PR, RT and IN, are processed as a 
single precursor protein together with the gag proteins (Nisole and Saib 
2004). 
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Figure 3. Scheme of the HIV genome, transcripts and proteins. (A) HIV transcripts. 
Integrated into the host chromosome, the 10-kb viral genome contains open reading frames 
for 16 proteins that are synthesized from at least ten transcripts. Black lines denote 
unspliced and spliced transcripts, above which coding sequences are given, with the start 
codons indicated. Of these transcripts, all singly spliced and unspliced transcripts shown 
above those encoding the transcriptional transactivator (Tat) require regulator of virion gene 
expression (Rev) for their export from the nucleus to the cytoplasm. The RNA target for Rev, 
the Rev response element (Barre-Sinoussi, Chermann et al. 1983), is located within the 
gene encoding envelope protein (Env). (B) HIV proteins. Group-specific antigen (Gag) and 
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Gag–Pol (polymerase) polyprotein precursors are processed by the viral protease into nine 
subunits: protease (PR), reverse transcriptase (RT), which contains RNAse H, integrase 
(IN), matrix (MA), capsid (CA), p2, nucleocapsid (NC), p1 and p6 (shown in the yellow box). 
Env is cleaved by he cellular protease furin into the surface (SU) gp120 and the  
transmembrane (TM) gp41 moieties (shown in the orange box). Tat is the main 
transcriptional regulator of the long terminal repeat (Cornell, Technau et al.). Its RNA target, 
the transactivation response (TAR) element, is present at the 5' end of all viral transcripts. 
Rev is the main nuclear-export protein and it regulates the shift between early and late viral 
gene expression. The viral-infectivity factor (Vif), viral protein r (Vpr), viral protein u (Vpu) 
and negative effector (Nef) proteins are known as accessory proteins because they are 
dispensable for viral growth in some cell-culture systems. Nevertheless, they have essential 
roles in viral replication and progression to AIDS in vivo. Arrows below polyprotein 
precursors point in the direction of their processing to mature proteins. Tev contains Tat, Env 
and Rev sequences and functions as Tat and Rev. Figure taken from (Peterlin and Trono 
2003). 
 
2.1.2 Replication of HIV-1 
The early phase of HIV-1 infection (Figure 4) is marked by the recognition 
and adsorption of the virus to the host cell membrane mediated by the 
cellular receptor CD4 as well as the co-receptors CXCR4 or CCR5 (Doms 
and Moore 2000).  During the attachment process, gp120 mediates the 
contact to the host cell by binding to the CD4 receptor and by an interaction 
with one of the secondary cellular co-receptor. The co-receptor binding is 
essential for the infection of CD4+ T helper cells (McDougal, Nicholson et al. 
1986) and permits either the infection of cells by binding to CXCR4 or by 
binding to CCR5 (Alkhatib, Combadiere et al. 1996; Feng, Broder et al. 
1996). The binding of gp120 to CD4 induces a change of conformation within 
the trimeric Env protein (Salzwedel and Berger 2000) that leads to the 
exposition of the viral co-receptor binding site (Kwong, Wyatt et al. 1998). 
This conformational change exposes a viral fusion peptide present in the 
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transmembrane (TM) unit of the protein, allowing the viral membrane to fuse 
with the host cell membrane (Kliger, Peisajovich et al. 2000).  
After fusion of the virus with the host cell membrane, the HIV-1 RT catalyzes 
the transcription of both genomic RNA strands into one double-stranded DNA 
molecule in the cellular cytoplasm. In addition, the RT bears an RNase H 
activity allowing degradation of RNA from DNA-RNA hybrid strands. The viral 
DNA associates with components of the so-called preintegration complex 
(IN, MA, RT) and is transported to the nucleus where the viral integrase 
cleaves the 5´and the 3´LTR of the double stranded viral DNA at their 
3´ends. Via the resulting ends, the viral DNA is integrated into the host cell 
genome. The late phase of the HIV infection cycle starts with the 
transcription of the regulatory genes tat and rev, and the accessory genes. 
The Tat protein stabilizes the elongation of viral mRNA and is an important 
regulatory element of HIV-1. In early stages of the infection cycle, Tat 
accumulates and binds to the TAR (trans-activating response) element on 
the newly synthesized mRNA (Peterlin and Trono 2003). This leads to the 
phosphorylation of the cellular RNA-polymerase II and finally to the 
stabilization of viral transcriptional elongation (see below). The Rev protein 
participates in the transport mechanism of viral mRNA from the nucleus to 
the cytoplasm. For this it binds to the Rev-response element (Barre-Sinoussi, 
Chermann et al. 1983) located on the mRNA encoding for the env gene. In 
this way, Rev serves as a regulator separating the translation of early genes, 
which depend on multi-spliced mRNA (i.e. Tat, Rev and Nef), from the 
translation of late genes (Gag, Pol, Env and some accessory proteins) which 
depend on single and un-spliced mRNA. 
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Figure 4. The infection cycle of HIV. The life cycle of HIV can be broadly divided into six 
essential steps, which are shown here in the figure: interaction, adsorption and entry into the 
cell (a); reverse transcription of RNA into DNA (b); integration (c); transcription, splicing and 
nuclear export (d); translation and encapsidation (e); and viral assembly and budding (f). 
Figure taken from (Balvay, Lopez Lastra et al. 2007). 
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In this late phase, the gp160 protein is transported to the ER and post-
translational processes are initiated i.e. glycosylation and cleavage of gp160. 
The resulting trimer of non-covalently bound gp120 and gp41 is transported 
to the cell surface by Golgi vesicles. The gag polyprotein is translated from 
an unspliced mRNA and attaches to the Gag/Pol fusion proteins. After viral 
assembly, the virus is directed to the cellular membrane for release or, as 
described recently, to the endosomes of the infected cells (Kramer, Pelchen-
Matthews et al. 2005). The final maturation of the infectious particle occurs 
outside the host cell when the viral protease cleaves the HIV polyprotein 
products (Ganser-Pornillos, Yeager et al. 2008) 
 
At least five different accessory proteins are known with distinct impacts on 
viral pathogenesis, evasion from the host immune response and on viral 
replication. The so-called negative factor protein (Nef) is an early phase 
protein that accumulates in the cytosol of the infected host cell. It actually 
increases viral replication and at the same time it decreases the expression 
of CD4 molecules on the host cell membrane by clathrin-mediated 
endocytosis (Daecke, Fackler et al. 2005). Thus CD4-Env complexes at the 
cell surface are prevented and the probability of a secondary HIV-1 infection 
of that particular host cell is reduced. Furthermore Nef downregulates the 
major histo-compatibility complex II (MHC-II) protein levels on infected cells 
and interacts with a variety of different cellular proteins. The viral infectivity 
factor (Vif) is encoded in a reading frame between the pol and the env gene. 
Vif mediates the proteasome depending degradation of a cellular 
deoxycytidine deaminase (APOBEC3G) and thus allows the production of 
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infectious viral particles in non-permissive cells (Mehle, Strack et al. 2004). 
The Vpr (virion associated protein r) binds to the nucleus import complex 
composed of nucleoporin and importin and it participates in the transport of 
the preintegration complex towards the nucleus. In addition the Vpr   
influences the host cell cycle by arresting it in the G2 phase. The Vpu (viral 
protein U) interacts with CD4 molecules in the ER and triggers their 
degradation to the ubiquitine-proteasome pathway, preventing generation of 
CD4-env complexes in the ER. Vpu is also necessary for releasing HIV 
particles from the cell surface (Wildum, Schindler et al. 2006; Schindler, 
Rajan et al. 2010). Vpu enhances the release of HIV-1 virions from infected 
cells by counteracting the function of the host cell factors involved in release 
restriction Task-1 (Hsu, Seharaseyon et al. 2004), UBP (Callahan, Handley 
et al. 1998) and the more recently described BST-2, also known as Tetherin 
(Neil, Sandrin et al. 2007; Van Damme, Goff et al. 2008).  
 
2.1.3 Course of HIV-1 Infection 
 HIV mainly infects CD4+ T helper cells, which are a key cell type in fighting 
infectious agents. The pattern of disease progression in HIV infection is 
generally divided into 3 phases: (a) primary infection, (b) clinical latency, and 
(c) AIDS (Pantaleo and Fauci 1996). Such a course of infection is 
characteristic of the so-called typical progressors who represent the majority 
of HIV-infected individuals (Figure 5). The average time from initial infection 
to AIDS progression in typical progressors is eight to ten years (Buchbinder, 
Katz et al. 1994). Based on studies involving large cohorts of HIV-infected 
individuals, three additional subgroups have been identified. These include 
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subjects who have an unusually rapid progression of disease (i.e. rapid 
progressors) (Phair 1994), those who do not experience progressive disease 
for many years following primary infection (i.e. long-term nonprogressors) 
(Buchbinder, Katz et al. 1994; Cao, Qin et al. 1995), and those who progress 
to AIDS within a time frame similar to typical progressors, but in whom both 
clinical and laboratory parameters remain stable for an unusually long period 
of time once disease progression has occurred (i.e. long-term survivors) 
(Figure 5) (Zucconi, Jacobson et al. 1994).  It has recently been described a 
subtype of this group, the so-called elite controllers, who are able to avoid 
immunodeficiency without the need for antiviral therapy (Deeks and Walker 
2007). 
 
Primary infection may be associated with a mononucleosis-like clinical 
syndrome (Clark, Saag et al. 1991). Due to the lack of specificity and the 
variable severity of the clinical syndrome, primary infection generally goes 
unnoticed. However, upon retrospective analysis of the clinical history, it is 
estimated that 50–70% of HIV-infected individuals experience a clinical 
syndrome of varying severity during primary infection (Clark, Saag et al. 
1991). 
  
Typical Progressors 
The majority (70–80%) of HIV-infected individuals belong to the group of 
typical progressors (Figure 5). They experience a six to eight years period of 
clinical latency (Buchbinder, Katz et al. 1994). However, despite the lack of 
symptoms, HIV infection is active as is indicated by the persistent replication 
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of virus and the progressive loss of peripheral CD4+ T cells (Embretson, 
Zupancic et al. 1993). Individuals with CD4+ T-cell counts >500 per µl of 
blood generally remain free of symptoms, whereas the appearance of 
constitutional symptoms is generally more frequent in individuals with CD4+ 
T-cell counts below 500 per µl. Progression to clinically apparent disease or 
AIDS-defining illness (CD4+ T-cell counts <200 per µl of blood) generally 
occurs within eight to ten years in typical progressors (Schnittman, 
Greenhouse et al. 1991). 
 
 
Figure 5. Course of HIV-1 Infection. In vivo the course of infection is characterized by the 
behaviour of the HIV viral load and the levels of CD4 positive cells. See text for figure 
details. Figure adapted from (Pantaleo and Fauci 1996) 
 
Rapid Progressors 
A significant percentage (10–15%) of HIV-infected individuals experience an 
unusually rapid progression to AIDS within two to three years after primary 
infection (Phair 1994). Rapid progressors may experience a prolonged acute 
viral syndrome; in addition, constitutional symptoms of variable severity may 
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persist after transition to the chronic phase of the infection (Figure 5). In 
rapid progressors the period of true clinical latency may be absent or very 
brief. Downregulation of the initial burst of viremia may not be very efficient in 
rapid progressors; even after the initial decrease, the levels of viremia may 
rise rapidly. Inefficient control of the initial burst of viremia and rapid rise in 
viremia within the first or second year after primary infection reflects a poor 
control of HIV infection by the immune system.  
 
Long-Term Non-progressors 
A small percentage (less than 5% on the basis of different cohorts) of HIV 
infected individuals do not experience progression of disease for an 
extended period of time (Buchbinder, Katz et al. 1994). Long-term non-
progressors have CD4+ T-cell counts that are within the normal range and 
are stable over time (Figure 5); in addition, they generally have low levels of 
viremia and preservation of lymphoid tissue architecture and immune 
function. From a clinical standpoint, long-term nonprogressors are 
asymptomatic. 
 
Long-Term Survivors 
It remains unclear why in a small percentage of subjects who experience the 
progression of HIV disease within a period of time similar to typical 
progressors, both clinical and laboratory parameters, although abnormal, 
remain stable for an extended period of time (Zucconi, Jacobson et al. 1994).  
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Elite Controllers 
It has been recently described a subset of HIV infected individuals who can 
achieve a long-term control of viremia and avoid immunodeficiency without 
the need for antiviral therapy (Deeks and Walker 2007). The data gathered 
from those persons with this phenotype indicate a strong relationship 
between virus control and the presence of certain host HLA class I alleles 
and CD8+ T cell responses generated through these alleles, as well as strong 
virus-specific CD4+ T cell responses. 
 
2.2 Genetic variability of HIV-1  
The continuous and erroneous replication of HIV-1 drives the rapid 
generation of mutant variants during the persisting infection.  This 
characteristic leads to the formation of a related but genetically distinct virus 
population termed “viral quasi-species” (Domingo, Sabo et al. 1978; 
Goodenow, Huet et al. 1989; Meyerhans, Cheynier et al. 1989). This feature 
makes the virus to consist of a wide range of genotypic and phenotypic 
variants, most importantly mutants with resistance to antiviral drugs and 
mutants that are able to escape immune recognition by CD8+ cytotoxic T 
cells and antibodies (Richman 1994; Richman 1994; Havlir and Richman 
1996).  
 
2.2.1 HIV-1 classification 
Based on the phylogenetic comparison of sequences from virus isolates, 
HIV-1 has been subdivided into three major sub-groups, named group M 
(main), group O (outlier) and group N (new) (Arien, Vanham et al. 2007). 
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Figure 6 shows the phylogeny of HIV-1 and its distant relationship to HIV-2 
and to the Simian Immunodeficiency Virus (SIV) from chimpanzee. Based on 
phylogenetic analysis of a large number of HIV-1 sequences collected over 
the years and the fact that the first identified HIV group M infection case 
dates from 1959, it is most probable that the founder of the HIV-1 group M 
crossed from chimpanzee to humans at some point during the beginning of 
the 20th century (Korber, Muldoon et al. 2000). 
 
 
Figure 6. Phylogenetic tree showing the relationship between HIV-1, HIV-2 and SIVcpz. 
Figure taken from (Arien, Vanham et al. 2007) 
 
Group M is the main cause of the HIV pandemic and has evolved into 9 
distinct subtypes (A, B, C, D, F, G, H, J and K) (figure 6) (Kijak and 
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McCutchan 2005). Subtype C is responsible for more than 50% of world wide 
infections, followed by subtype B, subtype A and subtype D. The highest 
diversity of HIV-1 subtypes and recombinants is seen in the central African 
countries, which is likely to relate to the long time period since the start of the 
HIV epidemic in that particular region. This extensive genetic variation shown 
by HIV is mainly due to the error mechanisms involved in HIV replication. 
 
2.2.2 Error mechanisms of HIV-1 
Three main mechanisms contribute to the genetic variability of HIV: i) point 
mutations, ii) hypermutation and iii) recombination. Point mutations arise due 
to the RT lack of proofreading activity, resulting in an estimated probability of 
wrong base incorporation into the newly transcribed DNA of about 0.25 per 
genome per round of replication (Mansky and Temin 1995). 
 
Hypermutation is a process tightly related to the function of the cellular 
proteins APOBEC3G and 3F (Harris and Liddament 2004).  During reverse 
transcription, these proteins function as cystidine deaminases triggering 
massive deamination of deoxycytidine to deoxyuridine within the retroviral 
minus-strand cDNA (Harris, Bishop et al. 2003). As a result, and during 
synthesis of the plus-strand cDNA, an adenine base is incorporated, thus 
producing vast amounts of G to A mutations (Harris, Bishop et al. 2003). This 
process has been shown to generate up to 700 G to A mutations per genome 
per round of replication (Vartanian, Henry et al. 2002), representing an error 
catastrophy for the viral genome. HIV counteracts this effect through the viral 
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protein Vif that binds to  APOBECG3 and 3F, and prevents the APOBEC 
proteins to be packaged inside the virions (Mariani, Chen et al. 2003). 
Recombination plays a pivotal role in the generation of HIV variability. During 
HIV reverse transcription, and due to its low processivity, the RT can “drop” 
from one RNA strand to continue the synthesis of the minus-strand DNA 
chain at the other RNA strand (Coffin 1979). This cross-over between both 
RNA strands can occur at a high rate of up to 30 events per genome per 
round of replication (Levy, Aldrovandi et al. 2004).  If multinfection of a single 
cell occurs, recombination may lead to the generation of mosaic proviruses 
carrying pieces of genetic information derived from different parental RNA 
genomes. 
 
2.2.3 HIV-1 multinfection of single cells 
HIV has the ability to infect a single cell more than once. Using fluorescence 
in situ hybridization (FISH) to quantify the provirus copy number per cell and 
PCR to test for sequence divergence, Jung et al. found a mean of 3 to 4 
provirus in splenocytes from two infected patients (Jung, Maier et al. 2002). 
Multinfection was also found to be common in SIVmac251 infected Rhesus 
macaques, in which after 29 weeks of infection more than 10% of the 
infected splenocytes harboured a mean of 2 provirus (Anke Schultz, PhD 
thesis, 2009).  
 
The main consequence of multinfection is the generation of recombinant 
forms of the virus. If at least two different HIV variants infect the same cell, 
this may lead to co-packaging of two distinct genomic RNA molecules into 
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the same virion. When this newly produced virus infects another host cell, the 
RT will copy both RNA strands to produce a single recombinant DNA 
provirus.  This process can also lead to the production of a mosaic progeny, 
not only at the genomic level, but also at the protein level, a process named 
phenotypic mixing (Novick and Szilard 1951).   
 
The precise mechanisms of HIV multinfection are not yet fully understood. 
Single cells might be infected more than once by sequential infections with 
free viruses and infected cells, or via cellular dynamic structures involved in 
cell-to-cell viral transmission in which multiple virions might infect by a single 
contact of atarget cell with an infected one (Dixit and Perelson 2004; 
Sourisseau, Sol-Foulon et al. 2007). It has been shown that HIV efficiently 
propagates between infected and uninfected CD4+ T cells and macrophages 
by the use of the so-called virological synapses and by interacting with 
cellular lipid rafts (Martin and Sattentau 2009). The virological synapse is a 
cellular structure appearing at the target-effector cell interface where Env, 
CD4 and co-receptor molecules are clustered. The directional cell-to-cell 
spread via the synapse accelerates the rate-limiting step of viral attachment 
(Sol-Foulon, Sourisseau et al. 2007), thus enhancing infection efficiency 
(Chen, Hubner et al. 2007). Lipid rafts are tightly packaged but dynamic 
micro domains in the cellular membrane. It major component is cholesterol 
among other lipids (Simons and Ikonen 1997). Carter et al showed an 
involvement of lipid rafts domains in HIV-1 entry in macrophages by co-
localizing virus particles with a lipid raft marker at an early time post-infection 
and by isolating CD4 and CCR5 molecules associated with the lipid rafts 
 22 
(Carter, Bernstone et al. 2009). Disrupting the lipid rafts by depletion of 
membrane cholesterol as well as inhibition of cholesterol synthesis showed a 
significant reduction in HIV entry and in surface expression of HIV receptors 
(Carter, Bernstone et al. 2009).  
 
Two other cellular dynamic structures that are involved in cell-to-cell virus 
spread have been suggested to play a role in HIV multinfection. These are 
filopodial bridges (Sherer, Lehmann et al. 2007) and T-cell membrane 
nanotubes (Sowinski, Jolly et al. 2008). The filopodial bridges originate from 
non-infected cells and interact, through their tips, with infected cells. There, a 
strong association between the viral envelope glycoprotein in an infected cell 
with the receptor molecules in a target cell have been shown to stabilize the 
bridge, allowing for viruses to move along the outer surface of the filopodial 
bridge towards the target cell (Sherer, Lehmann et al. 2007). Membrane 
nanotubes are formed when T-cells make contact with each other, and are 
known to connect various cell types, including neuronal and immune cells. T-
cell nanotubes are distinct from other cell types since a dynamic junction 
persists within the T-cell nanotubes allowing them to adopt variably shaped 
contours. HIV-1 transfers efficiently to uninfected T-cells through these 
nanotubes in a receptor-dependent manner (Sowinski, Jolly et al. 2008). 
 
2.2.4 HIV-1 robustness in the face of variation  
Despite its phenomenal genetic diversity at all levels, HIV demonstrates a 
remarkably robust phenotype. Robustness is the ability to function despite 
genetic perturbations. As discussed before, point mutations and 
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recombination events during reverse transcription of the viral genomic RNA 
contribute to this diversity, allowing HIV to evade selection pressures such as 
those exerted by antiviral drugs. Because mutations are usually deleterious, 
HIV has to keep a balance between replication errors and functionality. How 
this is achieved is poorly understood. 
 
Two mechanisms might be playing a role in the robustness of HIV: i) the 
fitness interactions between mutations (termed epistasis) (Elena, Carrasco et 
al. 2006; Elena, Sole et al. 2010), and ii) the masking and hiding of low 
fitness genotypes by phenotypic mixing (Wilke and Novella 2003).  This 
thesis work is focused on these two phenomena. 
 
2.3 Epistasis 
2.3.1 Definition of epistasis  
In general, epistasis is defined as the interaction between genes. However, 
the use of the word to describe different statistical and biological concepts 
often leads to misunderstanding among authors in the literature (Cordell 
2002). In his book Mendel’s Principles of Heredity, biologist William Bateson 
first introduced the term “epistasis” to describe a phenomenon in which the 
effect of a genetic variant in one locus was altered or cloaked by a genetic 
variant at another locus (Bateson 1909). The result is that a phenotype of a 
certain genotype in one locus is only evident in those variants with a certain 
genotype at the second locus. Table 1 shows a typical example of Bateson 
definition of epistasis.  The effect of genotype at locus A is only present for 
the B/B variant; if genotype at locus B is b/b or b/B then the effect of at locus 
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A is not evident. The effect of genetic variation at locus A can be masked by 
locus B, therefore it is said that locus B is epistatic to locus A.  In another 
words, if some gene or mutation combinations result in novel phenotypes, 
then those mutations must be interacting with each other within trails 
influencing the same phenotype. 
  GENOTYPE AT LOCUS B 
GENOTYPE AT LOCUS A B/B b/b or b/B 
A/A 1 0 
a/a or a/A 0 0 
 
Table 1. Example of the effect on the phenotype of different genotypes at two loci showing 
epistasis. 
 
Years later, in 1918, Ronald Fisher used the term “epistacy” to describe the 
deviation from additivity in the effect of alleles at different loci with respect to 
their contribution to a phenotype (Fisher 1918). Even when this definition is 
not equivalent to Bateson´s original definition of epistasis, many population 
geneticists adopted the term “epistasis” to describe the same phenomena 
(Phillips 1998). According to Fisher, under the null hypothesis of no epistatic 
interaction, the contribution of combinations of mutations to a certain 
phenotype follows a linear distribution in which mutations are independent 
and contribute multiplicatively to the resulting effect. Any deviation from this 
linear model is sign of mutational interaction. 
 
Recently, Patrick Phillips proposed three different categories in which the 
term epistasis might be applied: functional epistasis, compositional epistasis 
and statistical epistasis (Phillips 2008).  Functional epistasis describes the 
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molecular interaction between proteins operating within the same pathways 
or complexing with one another. Compositional epistasis describes the 
traditional use of epistasis for the masking or blocking of one allele effect by 
an allele at another locus. Statistical epistasis is the concept established by 
Fisher and is the one most often used in the microbiology field since it yields 
the appropriate measures to describe evolutionary change and solves the 
problem of having large amounts of genetic combinations in a natural 
population (such as in bacteria and viruses), which may not manifest strictly 
on the phenotype but have an impact on fitness.  
 
2.3.2 Types of epistatic interactions 
Epistasis might act in different directions. Figure 7 shows a schematic 
representation of the type of mutational interactions and their effect on fitness 
measured on a multiplicative scale.  If mutations interact so that their 
combined effect on fitness is greater than expected from their individual 
effects, then epistasis is said to be synergistic. By contrast, if mutations 
interact so that their combined effect is smaller than expected, then epistasis 
is called antagonistic. Depending on the nature of the mutations being 
deleterious or beneficial, the sign of epistasis can be positive or negative. 
When mutations are deleterious, synergistic interactions result in negative 
epistasis and antagonistic interactions result in positive epistasis. The 
contrary is true for beneficial mutations were synergistic interactions result in 
positive epistasis and antagonistic interactions result in negative epistasis 
(Michalakis and Roze 2004; Kouyos, Silander et al. 2007). 
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Figure 7. Type of epistatic interactions among mutations in a given genotype and their 
effect on fitness. Panel A shows the situation for deleterious mutations. Without epistasis 
(E=0), the accumulation of new mutations leads to a linear decrease in the mean fitness. 
Mutations can interact antagonistically making the effect on fitness smaller (E>0) or 
synergistically, making the effect greater (E<0). This leads to an increase or decrease of the 
expected fitness respectively. The opposite is true for beneficial mutations, but the sign of 
epistasis remains the same (Panel B). 
 
2.3.3 Epistasis in the context of HIV 
Epistatic effects have been observed in many fundamental biological 
processes like speciation (Gavrilets 2004), long-term selection in model 
organisms (Carlborg, Jacobsson et al. 2006), and in loci associated with 
human diseases (Badano, Leitch et al. 2006; Gregersen, Kranc et al. 2006; 
Cordell 2009). Epistatic interactions also have a central role in evolutionary 
topics such as the evolution of sexual reproduction (Otto and Gerstein 2006; 
de Visser and Elena 2007) and the structural evolution of genetic systems 
(de Visser, Hermisson et al. 2003; Ortlund, Bridgham et al. 2007).  
 
With respect to viruses, interactions between mutations are also common. 
Epistasis among viral loci has been found in many diverse viruses like the 
DNA bacteriophage Phi-X174 (Burch and Chao 2004), the RNA 
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bacteriophage Phi-6 (Silander, Tenaillon et al. 2007), the foot-and-mouth 
disease virus (Elena 1999), polio virus (Crotty, Cameron et al. 2001), 
vesicular stomatitis virus (Sanjuan, Moya et al. 2004), Chikungunya Virus 
(Tsetsarkin, McGee et al. 2009) and the human immunodeficiency virus (HIV) 
(Bonhoeffer, Chappey et al. 2004; van Opijnen, Boerlijst et al. 2006; Parera, 
Fernandez et al. 2007; Parera, Perez-Alvarez et al. 2009; da Silva, Coetzer 
et al. 2010). Although a wide range of mutational interactions (positive and 
negative) was observed, predominance for positive epistasis in viruses 
seems to be the trend.  Epistasis may directly impact viral robustness and the 
efficiency of variant selection under therapy (Sanjuan, Moya et al. 2004; 
Elena, Carrasco et al. 2006; Kouyos, Silander et al. 2007; Rolland, Brander 
et al. 2007; Elena, Sole et al. 2010) 
 
HIV is an ideal candidate to study epistatic interactions in viruses. First, the 
virus shows an extraordinary genetic diversity which is observed at all 
possible levels from between patient comparisons to even viral variants 
within multi-infected individual cells (Jung, Maier et al. 2002). This genetic 
diversity is accompanied by the capacity of HIV to rapidly adapt to changing 
environments. This is best exemplified by the rapid selection of escape 
mutants in response to antiviral drugs. Depending on the nature of the drug-
HIV interaction, it may require just few weeks to fix the resistant mutants 
within the viral population in vivo (Havlir and Richman 1996). Second, HIV 
grows easily in cell culture and assays to determine viral fitness are well 
established. Third, there is abundant data on HIV sequences and 
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characteristics within patients that allow estimating the consequences of 
epistatic interactions within infected hosts. 
 
Under the conditions of mutation-selection equilibrium, fitness interactions 
between mutations will affect the frequency of individual mutants within a 
virus population (Nowak 2000). A buffering effect of deleterious mutations is 
expected if epistasis would be positive. In this case, the abundance of 
deleterious mutants would be higher than expected and the viral population 
may respond faster to a new selection pressure supposing that the 
deleterious mutations would be beneficial under the new growth conditions. A 
clinically important example and test scenario for this is the selection of drug-
resistant HIV variants after the use of antiretroviral treatment. By using amino 
acid sequence data of the reverse transcriptase and protease regions of HIV-
1 isolates from infected individuals undergoing antiviral treatment and the 
corresponding fitness values measured in vitro in the absence of drugs, 
statistical evidence for the predominance of positive epistasis has been 
detected (Bonhoeffer, Chappey et al. 2004). However, a number of 
limitations of this study were raised. One major concern was the likely under-
representation of low fit variants in the data set that could have led to false 
conclusions towards epistasis (Wang, Mittler et al. 2006). Such a biased 
genome representation seems inevitably linked to the experimental 
procedure used to generate the genotype to phenotype correlations. A 
preference for the major viral mutants and thus more fit variants is simply 
obtained by PCR-mediated amplification and the direct cloning of the 
respective HIV regions into HIV vectors for subsequent fitness 
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measurements. Thereby the clonal sequence representation is expected to 
be directly proportional to the respective fitness of the variant in vivo. Other 
limitations of the study were (i) the lack of fitness values in the presence of 
drugs so that epistatic effects and their consequences could be compared 
with and without medication and (ii) the lack of knowledge of the direct path 
of mutation accumulation including all intermediate mutants. 
 
A straightforward and complementary approach to measure fitness 
interactions relies on the construction of HIV variants with all mutations along 
an evolutionary pathway, then measuring their individual and combined 
fitness effects, and comparing the results with predictions generated under 
the null hypothesis of non-epistatic interactions (Sanjuan, Moya et al. 2004).  
While this approach is experimentally feasible only for a limited number of 
variants and thus lacks completeness over all possible HIV mutation 
pathways, it is of highest resolution and captures all variants including those 
of very low fitness. The first part of this thesis work provides the results of the 
analysis of a specific mutation pathway that HIV follows within individuals 
after treatment with azidothymidine (AZT), a nucleoside-analog reverse 
transcriptase inhibitor. 
 
2.4 Phenotypic Mixing 
Phenotypic mixing might impact the evolution of a viral population (Bellew 
and Chang 2006; Elena, Carrasco et al. 2006). While mutation and 
recombination shape the HIV composition at the genomic level, multinfection 
of single cells can lead to another important process: if two distinct virions 
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infect the same cell the resulting progeny may exhibit phenotypic mixing 
(Brenner 1957; Zavada, Bubenik et al. 1975). Upon transcription and 
translation, the genomic RNA of one parental virion may be packaged 
together with proteins derived from the genome of the other parent to form a 
new emerging virion (Figure 8). As a result, functional products packaged in 
the resulting virion might complement the lack of function of the original 
phenotype such as, for example, failure to integrate due to a defective HIV 
integrase (Gelderblom, Vatakis et al. 2008) or complementation of defective 
HIV Reverse Transcriptases and Proteases (Julias, Ferris et al. 2001). In 
addition, this whole process might contribute to viral robustness by help to 
rescue certain viruses from extinction by maintaining deleterious and/or low 
fitness mutants in the population (Wilke and Novella 2003), exert immune 
escape and expand cellular tropism (Zavada 1982; Canivet, Hoffman et al. 
1990; Spector, Wade et al. 1990; Landau, Page et al. 1991; Markowitz, Mohri 
et al. 2005).  
 
Since its first detection in bacteriophages (Novick and Szilard 1951), 
phenotypic mixing has been described for Polio Virus (Ledinko and Hirst 
1961), Sindbis Virus (Burge and Pfefferkorn 1966), Food-and-Mouth Disease 
Virus (FMDV) (Wilke and Novella 2003), and also for HIV (Lusso, di Marzo 
Veronese et al. 1990; Lusso, Lori et al. 1990; Rayner, Cordova et al. 1997). 
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Figure 8. Schematic representation of the phenotypic mixing effect. A, if two different viruses 
infects the same cell, both parental RNA genomes get reversed transcribed into DNA and 
integrates into host cell chromosome. B, the proviruses begin to transcribe their  DNA by the 
use of the host cell transcription machinery. Some forms of the viral DNA may remain as 
unintegrated circular forms. These do not contribute significantly to virus transcription. C, 
finally the viral RNA is translated within the cytoplasm where full-length viral RNA and 
structural proteins are randomly assembled into new emerging virions. This random 
assembly results in the production of mosaic viruses that can carry RNA and proteins 
derived from different parental proviruses.  
 
For HIV and SIV, in vivo data show that multinfection of single cells is 
common (Jung, Maier et al. 2002). This suggests that, besides recombination 
between different proviruses, phenotypic mixing of viral products might be 
common in vivo as well.  Indeed, in silico simulations suggested that hiding of 
genetic material by phenotypic masking, that is when phenotypic traits 
derived from one provirus hide the genetic material of another provirus, might 
occur approximately 25% of the time (Bellew and Chang 2006). Modeling 
treatment with two different antiviral drugs showed that, as the treatment 
advance, an initial homogeneous population of virions (where the genotype 
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matched phenotype) was substituted by heterogeneous (phenotypically 
mixed) virions, which became dominant in the population throughout 
treatment (Bellew and Chang 2006).  
 
To understand how phenotypic mixing might help (and to what extend) to 
shape a virus population in an infected individual, it is important to unfold 
how this process can affect infectivity and replication. Research studies on 
HIV RTase and RNase H indicate that limiting polymerase activity by mixing 
wild type and mutant RTase affects DNA synthesis (Julias, Ferris et al. 
2001). Monitoring reverse transcription of phenotypically mixed virions by 
using real-time PCR showed that in HIV there is an excess of RTase and 
RNase H activity, suggesting a robustness strategy where an excess of 
enzyme activity compensates for the loss of function due to incorporation of 
mutant polymerase in the virions (Julias, Ferris et al. 2001).  Incorporation of 
mutant glycoproteins resistant to entry inhibitors or to antibody neutralization 
might result in escape mutants. In addition, phenotypic mixing can result in 
multidrug resistance and altered cellular tropism, which in turn may influence 
disease progression (Markowitz, Mohri et al. 2005). 
 
It is still not clear how different combinations of mutant RTase or surface 
glycoproteins may affect HIV infectivity and replication in the face of antiviral 
therapy.  A straightforward approach to analyze such effects is the 
generation of phenotypically mixed variants carrying combinations of wild 
type and drug-resistant RTases or envelope proteins in a specified ratio and 
to measure their effects on single-round infections with and without the 
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addition of antiviral drug pressure. The second part of this thesis presents the 
results of such study by quantifying the fitness and infectivity of HIV variants 
that were phenotypically mixed. This provides estimates of the size of the 
phenotypic mixing effect as it would be expected in vivo. 
 
2.5 Objectives 
The fitness interactions between mutations, referred to as epistasis, can 
strongly impact evolution. For RNA viruses and retroviruses with their high 
mutation rates, epistasis may be particularly important to overcome fitness 
losses due to the accumulation of deleterious mutations and thus could 
influence the frequency of mutants in a viral population. The relative 
abundance of deleterious mutants may allow for a faster response to a new 
selective pressure supposing that the deleterious mutations would be 
beneficial under the new growth conditions. A clinically important example 
and test scenario for this is the selection of drug-resistant HIV variants after 
the use of antiretroviral treatment. 
 
By masking the deleterious effects of mutations, phenotypic mixing could 
impact the dynamics of the viral quasispecies in an infected individual. 
Phenotypic mixing might contribute to i) the maintenance of low fitness 
variants, ii) immune escape, and iii) the cellular tropism of variants in a viral 
population. 
 
In this work three central questions concerning these issues of the HIV 
dynamics in infected cells were addressed:  
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1) What is the fitness of individual HIV mutants with no or a low drug 
resistance phenotype along a specific mutational pathway? Does 
different host cell environments influence the fitness? 
 
2) What is the nature of the epistatic effect on fitness of individual HIV 
drug-resistant variants? Are epistatic interactions powerful enough to 
change the expected frequency of HIV drug-resistant variants? 
 
3) What is the magnitude of the phenotypic mixing effect on fitness of 
HIV variants? To what extend does phenotypic mixing influences 
infectivity?  
 
To address these questions, the fitness of individual drug-resistant mutants 
was studied in the context of a classical mutational pathway, (the so-called 
41-215 cluster), that HIV follows upon treatment with the reverse 
transcriptase inhibitor azidothymidine (AZT). Fitness measurements were 
performed in single round infection assays covering physiological drug 
concentrations ex vivo in different types of cells.  The direction and 
magnitude of the epistatic effects were calculated based on the two-locus-
two-allele model and the frequency of variants with and without epistasis was 
assessed by applying a steady-state model of HIV quasispecies dynamics.  
 
The impact of phenotypic mixing on HIV infectivity and fitness was studied by 
constructing a set of virions containing up to 1:4-ratio combinations of 
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different wild type and resistant HIV glycoproteins and reverse 
transcriptases. To determine the effect of phenotypic mixing on envelope 
function and infectivity, viruses carrying mixes of wild type and entry inhibitor 
Enfurtivide (T20) were constructed and tested. To determine the effect on the 
replication capacities (fitness), viruses carrying mixes of wild type and AZT-
resistant RTases were tested. Finally, viruses containing mixes of both AZT-
resistant RTases and T20-resistant glycoproteins were used to investigate 
the effect of phenotypic mixing on a simplified scenario that mimics the 
situation of a combination therapy. 
 
Altogether, this thesis presents new insights on fitness behavior, epistatic 
and phenotypic mixing effects of HIV drug-resistant mutants and provides 
high-resolution data that can be incorporated into a complete mathematical 
model of HIV dynamics in patients. 
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3. Materials and Methods 
3.1 Chemical reagents 
Agarose     Applichem, Darmstadt  
Ampicillin (Binotal™)   Ratiopharm, Ulm 
CaCl2     Merck, Darmstadt  
Glacial Acetic Acid   Merck, Darmstadt  
Chloroform     Merck, Darmstadt  
DMEM     Gibco® Invitrogen, Karlsruhe  
DMSO     Applichem, Darmstadt  
Ethanol     Roth, Karlsruhe  
EDTA     Merck, Darmstadt  
EtBr      Sigma-Aldrich, München  
FCS      Invitrogen, Karlsruhe  
HEPES    Gibco, Invitrogen, Karlsruhe  
HCl      Merck, Darmstadt  
Iso-Propyl alcohol   BMLS-Dar Es Salaam 
IL-2 (Proleukin®)    Chiron Behring, Marburg  
Isopropanol     Merck, Darmstadt  
KCl      Merck, Darmstadt  
LB-Agar     BD, Sparks, USA  
LB-Medium     BD, Sparks, USA  
L-glutamine    Gibco, Invitrogen, Karlsruhe 
Methanol     Merck, Darmstadt  
MgCl2     Merck, Darmstadt  
NaCl      Applichem, Darmstadt  
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NaOH     Merck, Darmstadt 
PBS     Sigma, Deisenhofen 
Penicillin/Streptomycin  Biochrom AG, Berlin  
Phenol     Merck, Darmstadt  
PHA      Difko, Detroit, MI. USA  
RPMI 1640     Lonza, Velviers, Belgien  
RbCl      Merck, Darmstadt  
Saccharose     Roth, Karlruhe  
SDS      Applichem, Darmstadt  
TRIS      ICN Biomedicals Inc., Ohio, USA  
Triton X-100     Applichem, Darmstadt  
Tween20     Merck, Darmstadt  
 
3.2 Experimental Design 
3.2.1 Approach to quantify relative fitness of HIV-1 RT mutants 
To measure the fitness of the HIV-1 RT mutants along the 41-215 AZT 
resistance pathway, the respective variants were generated by site-directed 
mutagenesis PCR (Ho, Hunt et al. 1989). The PCR products were cloned 
into the HIV-1 viral vector TN7-Stopp that carries the Renilla luciferase 
reporter gene instead of the HIV-1 Nef gene and lacks a functional HIV-1 Env 
gene (Figure 9A) (Neumann, Hagmann et al. 2005). The HIV pseudotypes 
were produced by co-transfection of the TN7-Stopp plasmid in 293T cells 
together with an HIV-1 Env expression plasmid. The resulting virus stocks 
were used to infect PBMC and TZM-bl as target cells without the addition of 
AZT and under physiological concentrations of the drug (Figure 9B). The 
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fitness values of the wild type and mutants were quantified by measuring the 
relative luciferase activity as their replication capacity in a single-cycle 
infection assay. To obtain the final relative fitness values of all variants, the 
mean fitness of the mutants were normalized to the mean fitness of the wild 
type without drug (See section 3.11 statistical analysis). 
A 
B 
 
Figure 9. Experimental approach followed for the HIV-1 pseudotype production, 
infection and fitness measurements. A) Schematic representation of the TN7-Stopp HIV- 
based expression plasmids. Light blue boxes indicate the mutations introduced in the RT 
gene. The red X indicates the site in the Env gene where the insertional mutations are 
placed. B) Representation of the protocol for pseudotype production, titration and infection 
experiments (see text for details). 
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3.2.2 Approach to quantify phenotypic mixing effects on fitness 
For the purpose of assessing the impact of phenotypic mixing on HIV 
infectivity and fitness, a set of three different experiments was designed 
(Figure 10). First, 22 single-round pseudotype viruses carrying specific mixes 
of wild type, M41L and M41L-T215Y AZT-resistant RTases were constructed 
to quantify the effect of phenotypic mixing on fitness without AZT and with 
the addition of drug (Figure 10, number 1).  
 
Figure 10. Schematic representation of the three approaches followed to study 
phenotypic mixing effects on infectivity and fitness (see text for details). 
 
Second, a set of 5 single-round pseudotype viruses carrying mixes of wild 
type and the entry inhibitor Enfurtivide (T20)-resistant envelopes were used 
to quantify the effect of phenotypic mixing on envelope function and 
infectivity (Figure 10, number 2). Finally viruses constructed with mixes of 
both AZT-resistant RTases and T20-resistant glycoproteins were used to 
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investigate the effect of phenotypic mixing on a simplified scenario that 
mimics the situation of a combination therapy (Figure 10, number 3). The 
production of phenotypically mixed pseudotypes and quantification of their 
effects was performed by following the general procedure described in 
section 3.2.1. 
 
3.3 Plasmids 
The source and the characteristics of the plasmids used in this work are 
described in Table 2. 
Table 2. Plasmids used in this thesis work.  
PLASMID DESCRIPTION SOURCE 
pTN7-Stopp HIV-1 NL4-3 based viral vector 
carrying the luciferase gene in the 
position of the nef gene 
Dr. M T. Dittmar, 
Heidelberg 
pEnv035x Plasmid expressing a HIV CCR5-
tropism envelope 
Prof. C. Jassoy, Leipzig 
pEnv035xMut Plasmid expressing a HIV CCR5-
tropism envelope carrying a mutation 
which confers resistance to the entry 
inhibitor T20 
Prof. C. Jassoy, Leipzig 
pGEM-T Cloning vector carrying the SP6 and 
T7 promoters and T-overhangs for 
cloning of PCR products 
Promega 
pGEM-41L Cloning vector carrying the M41L 
mutation of the HIV RTase 
(1) 
pGEM-215N Cloning vector carrying the 215N 
mutation of the HIV RTase 
(1) 
pGEM-215S Cloning vector carrying the 215S 
mutation of the HIV RTase 
(1) 
pGEM-215Y Cloning vector carrying the 215Y 
mutation of the HIV RTase 
(1) 
 
pGEM-41L-215N Cloning vector carrying the 41L and 
215N mutation of the HIV RTase 
(1) 
pGEM-41L-215S Cloning vector carrying the 41L and 
215S mutation of the HIV RTase 
(1) 
pGEM-41L-215Y Cloning vector carrying the 41L and 
215Y mutation of the HIV RTase 
(1) 
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Table 2. Continuation. 
PLASMID DESCRIPTION SOURCE 
pTN7-41L pTN7-Stopp carrying the M41L 
mutation of the HIV RTase 
(1) 
pTN7-215N pTN7-Stopp carrying the 215N 
mutation of the HIV RTase 
(1) 
pTN7-215S pTN7-Stopp carrying the 215S 
mutation of the HIV RTase 
(1) 
pTN7-215Y pTN7-Stopp carrying the 215Y 
mutation of the HIV RTase 
(1) 
 
pTN7-41L-215N pTN7-Stopp carrying the 41L and 
215N mutation of the HIV RTase 
(1) 
pTN7-41L-215S pTN7-Stopp carrying the 41L and 
215S mutation of the HIV RTase 
(1) 
pTN7-41L-215Y pTN7-Stopp carrying the 41L and 
215Y mutation of the HIV RTase 
(1) 
(1) Generated during this thesis work in the Institute for Virology, Homburg.  
 
3.4 Cells and bacteria 
3.4.1 Cell lines 
293T cell line. 293T is a cell line derived from human embryonic kidney cells 
transformed by the adenovirus E1A gene. The cells stably express the large 
T-antigen of SV40 and are optimized for efficient transfection and production 
of lentiviral vectors. Therefore, these cells were chosen for the production of 
virus stocks used in this work. 
 
TZM-bl cell line. TZM-bl is an indicator cell line previously designated JC53-
bl clone 13. The TZM-bl cell line is a HeLa cell clone engineered to stably 
express CD4, CXCR4 and CCR5. These cells enable simple and quantitative 
analysis of HIV replication by an integrated copy of the long terminal repeat 
linked to a luciferase reporter gene. Expression of the indicator luciferase 
gene is under the control of the Tat protein that is expressed after HIV 
infection and viral DNA integration into the cell chromosome. These cells 
were used for titration of virus stocks and infection experiments. 
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3.4.2 Bacterial strains 
The source and the characteristics of the bacterial strain used in this work 
are described in Table 3 
Table 3. Bacterial strain used in this thesis work. 
NAME PROPERTIES SOURCE 
 
E. coli ER2925 
Genotype: ara-14 leuB6 fhuA31 
lacY1 tsx78 glnV44 galK2 galT22 
mcrA dcm-6 hisG4 rfbD1 R 
(zgb210::Tn10)TetS endA1 rpsL136 
dam13::Tn9 xylA-5 mtl-1 thi-1 mcrB1 
hsdR2 
Dam/dcm methylation: dam- / dcm- 
 
New England Biolabs 
 
3.5 Cell culture 
Cell culture is the growing of cells in vitro. In these conditions, the cells grow 
usually in monolayer attached to the flask surface (for adherent cells) or 
suspended in the medium (for suspension cells). The cultivation of cells is 
performed in a cell incubator at a temperature of 37 °C and with 5% CO2. 
 
3.5.1 Medium and buffers 
PBS-Buffer (w/o Mg2+ und Ca2+):  
NaCl   0.14 M  
KCl   2.7 mM  
Na2HPO4  0.1 mM  
KH2PO4  1.8 mM  
Solution is prepared with distilled water and brought to pH 7.4 by addition of 
HCl.  
Freezing medium  
RPMI 1640 
Heat-inactivated FCS 20 % (v/v) 
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DMSO              10% (v/v) 
Penicillin              100 U/ml 
Streptomycin              100 µg/ml 
Gentomycin              0.25% (v/v) 
 
DMEM medium 
DMEM w/o L-Glutamin  
Heat-inactivated FCS        10 % (v/v) 
L-Glutamine     2 mM 
Penicillin     100 U/ml 
Streptomycin       100 µg/ml 
 
RPM1 medium  
RPMI 1640 
Heat-inactivated FCS          10 % (v/v) 
L-Glutamine     2 mM 
Hepes buffer                                            10 mM 
Penicillin              100 U/ml 
Streptomycin       100 µg/ml 
 
Foetal Calf Serum was heat-inactivated for 10 min at 40°C. For transfection 
and infection experiments, medium was prepared without the addition of 
antibiotics. 
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Trypane Blue solution  (prepared with double distilled water) 
Trypane blue 0.36 % (w/v) 
NaCl 0.9 % (w/v) 
Trypane Blue solution was sterile filtrated with a syringe micro-filter 
 
3.5.2 Suspension cells 
PBMC were cultured in RPMI medium. Cells were controlled for viability, 
spun down, washed with PBS solution and split in a 1:10 ratio with new 
medium every 2-3 days. 
 
3.5.3 Adherent cells 
293T cells and TZM-bl cells were cultured with DMEM medium. Cells were 
controlled for viability, washed with PBS, detached from the culture flask 
surface by a short incubation with Trypsin/EDTA and split in a 1:10 ratio with 
new medium every 2-3 days.  
 
3.5.4 Cell counting 
Cells were counted after Trypane blue staining in a microscope cell counting 
chamber (Neubauer chamber or haemocytometer). Trypane blue exclusively 
stains dead cells. The cell counting chamber has 4 quadrants, with each 
quadrant having a grid of 16 squares. 10 µl of cell samples was diluted into 
90 µl Trypane blue, mixed well and added below the coverslide. For each 
sample all 4 quadrants were counted. The cell concentration is calculated 
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from the mean number of cells/quadrant multiplied by 10000 and the dilution 
factor.  
 
3.5.5 Freezing and thawing cells 
3.5.5.1 Freezing cells  
In order to maintain the library of cells used in the laboratory, cells were 
aliquoted and cryopreserved in liquid nitrogen.  
 
Protocol 
-  Cells were counted and spun down at 1400 rpm for 6 min. 
-  Supernatant was discarded and cells were washed once with PBS and 
spun down at 1400 rpm for 6 min. 
- Supernatant was discarded and cells were resuspended in ice cold freezing 
media (10
7
 cells/ml of freezing media). 
- Cells were transferred to a freezing tube with the date, cell amount and cell 
type and frozen in a styropor (BASF) rack directly at -70°C. 
- After 24 hours, the tubes were transferred to the liquid nitrogen tank for 
further storage. 
 
3.5.5.2 Thawing cells 
Vials of frozen cells were quickly thawed in hand and transferred into 10ml of 
a 37°C pre-warmed medium. Cells were spun down for 10 min at 900 rpm 
and the supernatant discarded. Cell pellets were washed two times with 
PBS, between centrifugations of 6 min at 1400 rpm, and transferred into the 
appropriate culture flask in RPMI or DMEM medium for subsequent culture.  
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3.5.6 Mycoplasma test 
Before freezing, all cells were assayed for mycoplasm contamination by 
sampling of the cell cultures and performing a PCR-based test with primers 
specific for several strains of mycoplasm (VenorGeM, Minerva Biolabs). 
Mycoplasma contamination in cell cultures influences the metabolism of cells 
and interferes with cell growth and cell behaviour in immunological and 
biochemical assays. Therefore it was recommended to test periodically the 
cells for mycoplasma by PCR. The VenorGeM PCR kit contains 
mycoplasma-specific primers recognizing Acholeplasma laidiawii, 
Mycoplasma synoviae, Mycoplasma hyorhinis, Mycoplasma arginini, 
Mycoplasma orale, Mycoplasma fermentans, Mycoplasma hominis and 
Mycoplasma salivarium. The product of this PCR is 264-275bp long 
(dependent on the species). The PCR will also produce a product of 191 bp, 
an internal control. The cells have to be cultured without antibiotics for 4-5 
days prior to testing, since they might inhibit the growth of mycoplasma to 
below the detection limit. The supernatant of adherent cells can be directly 
used for the PCR, but the supernatant of suspension cells had to be cleaned 
up first with Qiamp DNA blood Mini Kit (Qiagen). 
 
Protocol: 
PCR-Mix: 
 10x Reaction buffer  5µl 
 Primer/Nucleotide Mix  5µl 
 Internal control DNA  2µl 
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Sample    2µl 
 Taq Polymerase (5 U/µl)  0.2µl 
H20     up to 50µl 
Thermocycling conditions: 
 1 cycle  94°C, 2 min 
 35 cycles            94°C, 30 sec. 
 1 cycle             55°C, 30 sec. 
 1 cycle             72°C, 30 sec. 
 Cool down to 4°C 
 
For the visualization of the results, a 1.5% agarose gel (5 mm thick, 5 mm 
comb) was prepared and samples run at 100-120V. 10 µl of loading buffer 
was added to the samples. Individual concentrations of buffer are specified in 
the manual of the Qiagen kit.  
 
Procedure: 
- Adherent cells: 
-100 µl of cell culture supernatant in an 1,5ml reaction tube, incubate for 5 
min at 100°C, centrifuge down for 5 sec at 13000 U/min. Supernatant can be 
used now for PCR. 
- Suspension cells: 
- 200 µl of cell culture supernatant was incubated for 5 min at 100°C.  
- 200 µl buffer AL + 20 µl Protease was added and the mix vortexed for 15 
sec, incubated at 56°C and spun down for 10 min.  
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- 200 µl of ethanol was added and the mix vortexed for 15 sec. After another 
centrifugation step, the supernatant was added to a spin column in a 
collection tube and centrifuged for 1 min at 6000 rpm.  
- The spin column was put into a new collection tube and 500 µl buffer AW1 
was added. The tube was centrifuged for 1 min at 6000 rpm. 
- The spin column was put in a new collection tube and 500 µl buffer AW2 
was added. The tube was centrifuged for 3 min at 20000 rpm. 
- The spin column was put in a new collection tube and 200 µl buffer AE was 
added. After 1 min incubation at room temperature, the tubes were 
centrifuged for 1 min at 600rpm. The tube was centrifuged for 1 min at 6000 
rpm. After this step, the collected supernatant could be used for the PCR. 
 
3.6 Isolation of PBMC from “Buffy coats” 
The PBMC were obtained from buffy coats. Infection of Peripheral Blood 
Mononuclear Cells (PBMC) from healthy blood donors with the HIV-1 
pseudotypes was a major part of this work. A Buffy coat is the resulting 
fraction of anticoagulated blood after density gradient centrifugation, 
containing concentrated leucocytes. The Buffy coats were obtained from the 
blood bank of the Winterbergklinik, Saarbrücken. Blood donors were HIV-1, 
HIV-2, HBV and HCV negative. 
 
Protocol: 
- For each Buffy-coat 4 x 15 ml PBS and 4 x 15 ml Ficoll (Sigma, 
Deisenhofen) were prepared in 50 ml falcon tubes.  
- Each PBS falcon was filled up with 20 ml of blood and mixed by inversion. 
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- The PBS/blood mixture was carefully added to the Ficoll-containing tubes 
and centrifuged 1 hour at 1800 rpm 
- 10 ml of the supernatant phase was removed and the leucocytes ring 
collected using a 10 ml pipette avoiding the uptake of Ficoll. 
- The collected ring was put into 50ml falcons with PBS and centrifuged for 6 
min at 1600 rpm. 
- The supernatant was carefully discarded and each pellet resuspended in 5 
ml of H2O for erythrocyte burst.  
- Falcons were directly filled with PBS and repeatedly centrifuged for 6 min at 
1600 rpm until the cell pellets lost the characteristic red color. 
- Cells were resuspended in 50 ml of PBS and centrifuged for 10 min at 900  
rpm 
- The supernatant was decanted and the PBMC were then re-suspended in 
30-50 ml of pre-warmed (37°C) RPMI medium and cultured at 37°C and 
4.5% CO2 until PBMC were further used for experiments or treated for 
cryopreservation.  
 
3.7 Generation of wild type and drug resistant mutants 
3.7.1 Site-directed PCR mutagenesis:  
PCR site-directed mutagenesis was used to introduce the desired nucleotide 
changes at codons 41 and 215 of the reverse transcriptase gene of the HIV-1 
NL4-3 molecular clone as template. This technique involves two PCR 
reactions using overlapping primers (Figure 11 and Table 4 for primer 
details), as follows: in the first PCR step (PCR 1a), a 1062 base pair 
fragment containing the desired region of the HIV-1 RT was amplified using a 
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5' primer carrying a unique restriction site for the BclI restriction enzyme 
(New England Biolabs) and the 3' overlapping primer carrying the desired RT 
mutation (Figure 11). In parallel, another PCR (PCR 1b) used the 3' primer 
carrying the restriction site for the AgeI restriction enzyme (New England 
Biolabs) and the 5' overlapping primer carrying the other desired RT 
mutation. The resulting fragments were isolated from an agarose gel and 
used as templates in the second PCR (PCR 2) with only the 5' BclI and the 3' 
AgeI primers giving rise to the final template.  
 
Figure 11. Representation of the site-directed PCR strategy. See text for details. 
 
Table 4. Sequences of the primers used in this work. 
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Protocol (for each mutant): 
- First PCR (PCR 1a and PCR 1b) 
Mix:  
Buffer 10x     5 µl 
dNTPs (25 mM)    1 µl 
5´ Primer (15 pmol)    0.5 µl 
3´ Primer (15 pmol)    0.5 µl 
Taq-polymerase (5 U/µl, Roche)   0.5 µl 
Template (1 pmol)    1 µl 
H2O       up to 50 µl 
Thermocycling steps:  
94°C for 2 min  
30x cycles   94°C 30 sec 
58°C 30 sec 
68°C 45 sec 
Final elongation step: 68°C for 7 min  
 
- Second PCR (PCR 2) 
Mix 
Buffer 10x     5 µl 
dNTPs (25 mM)    1 µl 
5´ Primer (15 pmol)    0.5 µl 
3´ Primer (15 pmol)    0.5 µl 
Taq-polymerase (5 U/µl, Roche)   0.5 µl 
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Fragment PCR 1a (0.5 pmol)   2 µl 
Fragment PCR 2b (0.5 pmol)  2 µl 
H2O       up to 50 µl 
Thermocycling steps:  
94°C for 2 min  
30x cycles   94°C 30 sec  
50°C 30 sec  
72°C 60 sec  
Final elongation step: 68°C for 7 min.  
 
Samples were run on an agarose gel, isolated (Section 3.7.2) and 
commercially sequenced by dideoxy-sequencing (GATC Biotech, AG, 
Konstanz, Germany). The restriction sites introduced in the primers were 
used for the subsequent cloning of the mutated fragments.  
 
3.7.2 Isolation of PCR fragments from agarose gels 
Agarose gel electrophoresis allows the separation of charged molecules 
(such as DNA at neutral pH) in an electric field. The migration along the gel is 
dependent on net charge, size and shape of the nucleic acids and the gel 
matrix.  
 
Protocol: 
Buffers 
- 50X TAE Buffer 
Tris/HCL (pH 7.8)  2 M 
 53 
Na-acetate   0.25 M 
EDTA   0.5 M 
Procedure 
For identification of the PCR products and subsequent cloned vectors, a 
standard electrophoresis gel of 1% agarose inside a gel chamber with 1X 
TAE Buffer was used. DNA was stained by ethidium bromide (EtBr) at a final 
concentration of 0.7 µg/ml in 1X TAE Buffer. To visualize the running 
samples and increase their density, for loading the gel, samples were mixed 
with 1:5 volume of blue marker. A DNA Ladder of 1000 bp/1 Kb (GeneOn, 
Ludwigshafen) was used as a molecular weight standard, normally at the first 
and last lanes of the gel. Electrophoresis was carried out at 8 V/cm in 1 X 
TAE buffer and visualization of DNA-EtBr complexes was done under UV 
light. The fragments of gel with the corresponding PCR products were then 
cut out with a scalpel and the DNA purified with the use of a gel extraction kit 
from Qiagen (QIAquick Spin Gel Extraction Kit).  
 
3.7.3 Cloning:  
The cloning procedure followed two main steps: 
- First, the products from PCR 2 were ligated into the pGEM-T vector 
(Promega) via TA cloning. The bacterial strain E. coli ER2925 (New England 
Biolabs) was transformed with the plasmids and selected on ampicillin agar 
plates. Plasmid DNA was extracted using the alkaline method. Samples were 
run on an agarose gel, isolated and sequenced by dideoxy-sequencing 
(GATC Biotech, AG, Konstanz, Germany).  
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- Second, pGEM-T plasmids containing the desired RT mutants were 
digested with the restriction enzymes AgeI and BclI (New England Biolabs) 
and the respective fragments were cloned into the pTN7-Stopp HIV-1 
expression plasmid using the same restriction sites.  
 
3.7.3.1 Ligation of PCR fragments into pGEM-T (Promega) 
A peculiar property of Taq DNA polymerase is that, when DNA fragments are 
generated by PCR, the enzyme introduces one or two extra dATP 
deoxynucleotides onto the 3'-end of blunt double-stranded DNA in a 
template-independent manner. pGEM-T is a linearized vector with single 3´-
terminal thymidine at both ends. These T-overhangs improve the efficiency of 
ligation of PCR products by preventing recircularization of the vector and 
providing compatible oberhangs. 
 
Protocol: 
Product: 
- pGEM-T Vector System 
pGEM-T Vector   1.2 µg (50 ng/µl) 
Control insert DNA  12 µl (4 ng/µl) 
T4 DNA Ligase (4 U/µl) 100 units 
2 X Rapid Ligation Buffer 200 µl 
- Mix (each sample) 
2 X Ligation buffer   5 µl 
pGEM-T vector  1 µl 
PCR product   3 µl 
 55 
T4 DNA Ligase     1 µl 
H20     up to 10µl 
 
Procedure:  
The ligation of PCR products with pGEM-T was performed as indicated in the 
pGEM-T and pGEM-T Easy Vector Systems Technical Manual (Promega, 
#TM042, www.promega.com/tbs/tm042/tm042.pdf). The ligation reactions 
were mixed by pipetting and incubated overnight at 40C. 
 
 3.7.3.2 Transformation of E. coli ER2925 (New England Biolabs) 
Transformation of pGEM-T plasmids carrying the ligated PCR products was 
performed following the Rubidium Chloride (RbCl) method, which is very 
efficient due to the alkali-ions inside the buffer increasing the uptake of DNA 
by the bacteria.  
 
Protocol: 
Buffers 
- Transformation Buffer 1 
RbCl    0.1 M 
MnCl2   0.05 M 
CaCl2    0.01 M 
CH3COOH   0.03 M (pH 7.5 with NaOH) 
Glycerin   15 %(v/v) 
H20 sterilized and filtered 
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- Transformation Buffer 2 
MOPS (pH 6.8)  0.01 M 
RbCl    0.01 M 
CaCl2    0.075 M 
Glycerin   15 %(v/v) 
H20 sterilized and filtered 
 
Procedure: 
To generate competent bacteria, 100 µl of bacteria was precultured in 20 ml 
LB medium at 370C overnight. 8 ml of the precultured was scaled to 200 ml 
with LB medium and incubated for 1-2 hours at 370C on a shaker platform. 
After measuring an OD550 of 0.3, the cells were incubated on ice for 15 min 
and centrifuged 5 min at 2000 rpm. The bacterial pellet was resuspended in 
16 ml of the transformation buffer 1, incubated on ice for 15 min and 
centrifuged again. The cells were inoculated in 4 ml of the transformation 
buffer 2 and 50 µl aliquots were placed and stored in eppendorf tubes.  
Each bacteria aliquot was mixed with 10-50 ng of the desired DNA plasmids 
and incubated in ice for 30 min. Then, the mix was incubated for 90 sec at 
420C (heat shock), allowing the plasmid DNA to enter through the bacterial 
membrane pores. Immediately after the heat shock, the cells were incubated 
on ice for another 5-10 min and the mix incubated for 1-2 hours in 1 ml LB-
medium. This last incubation step allows the bacteria to express the resistant 
gene inserted into the plasmid. The bacteria were plated on a 10 cm dish 
with LB-agar containing antibiotics and incubated at 370C overnight. Only 
those bacteria that were efficiently transformed with the plasmid grew 
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colonies. The pGEM-T-containing bacteria were additionally identified by 
blue/white screening by inactivating the α-peptide coding region of the ß-
galactosidase enzyme that these plasmids carry. Selected colonies were 
picked from the plates and inoculated in 5 ml of LB medium for overnight 
growing.  
 
3.7.3.3 Plasmid isolation with the alkaline method 
To obtain the plasmid DNA, it has to be separated from the bacterial genomic 
DNA. By increasing pH and adding suitable reagents, the cells are lysed and 
the DNA and proteins denaturized.  Once this process is neutralized, the 
plasmids reconstitute easily due to their small sizes, regaining their circular 
form and remaining in the solution. Genomic DNA, proteins and other 
bacterial products are lost from the resulting solution.  
 
Protocol: 
Buffers:  
- STET Buffer 
Saccharose   8 %(w/v) 
Tris-HCL   50 mM (pH 8.0) 
EDTA   50 mM 
Triton X-100   0.1 % (v/v) 
- Solution 1 
NaOH   0.2 N 
SDS    1 %(w/v) 
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- Solution 2 
K-acetate   0.3 M (pH 4.8) 
LiCl    9.0 M 
 
Procedure: 
The 5 ml overnight culture was centrifuged 5 min at 5000 rpm and the cell 
pellets were resuspended in 150 µl of the STET buffer. By adding 250 µl of 
the Solution 1 to the mix and 5min incubation at room temperature the cells 
are lysed. The neutralization is achieved by adding 350 µl of Solution 2 and 
30 min incubation on ice. By centrifugation of the resulting solution, the 
bacterial genomic DNA and proteins are separated from the plasmid DNA 
that in turn was precipitated by the addition of 95 % ethanol. The plasmid 
DNA was washed in 70 % ethanol, dried and resolved in 20 µl of RNaseA- 
containing water.  
 
3.7.3.4 Sub-cloning into the HIV vector pTN7-Stopp 
The pGEM-T plasmids containing the desired RT mutants were digested with 
the restriction enzymes AgeI and BclI (New England Biolabs) and the 
respective fragments were cloned into the pTN7-Stopp HIV-1 expression 
plasmid using the same restriction sites. Digestion by these two enzymes 
produces two fragments: one of 1060 bp carrying the insert with the desired 
mutations, and another of 3000 bp (for pGEM-T) and 12000 bp (for pTN7-
Stopp) carrying the linearized plasmid vectors.  
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Protocol: 
Enzymes  
A list of the restriction enzymes used in this work is listed in Table 5.  
Table 5. Properties of the restriction enzymes used in this study. 
ENZYME SEQUENCE CUT SITE PROPERTIES 
Age I ACCGGT A/CCGGT              
TGGCC/A 
Optimal at 370C, 
suitable for 
extended digestion. 
No star activity 
BclI TGATCA T/GATCA 
ACTAG/T 
Optimal at 500C, 
suitable for 
extended digestion. 
No star activity. 
 
Enzyme Buffer: 
K-acetate   50 mM 
Tris-acetate   20 mM 
Mg-acetate   10 mM 
Dithiothreitol   1 mM 
pH    7.9 
Mix: 
Enzyme buffer  1.5 µl 
BSA    0.2 µl 
AgeI    0.5 µl 
BclI    0.5 µl 
Plasmid DNA  5µl (0.5 ng/µl) 
H20    up to 20 µl 
Procedure: 
- The mixes of pGEM-T (carrying the insert with the mutations) and 
pTN7-Stopp plasmids were first incubated for 2 hours at 370C to allow 
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digestion by the AgeI enzyme. After this first incubation, the 
temperature was raised to 500C to allow an optimal enzymatic activity 
of BclI. 
- The digested samples were run on an agarose gel and the desired 
fragments (insert and vector) isolated as described in section 3.7.2. 
The inserts were then ligated to the vector in a 3:1 ratio following a 
similar approach as described in section 3.7.3.1. 
- Ligation products (the reconstituted pTN7-Stopp plasmid with the 
corresponding inserts) were then transformed in E.coli ER2925 as 
described in Section 3.7.3.2 and plasmids isolated as described in 
Section 3.7.3.3.  
- The pTN7-Stopp plasmids were sequenced by dideoxy-sequencing 
(GATC Biotech, AG, Konstanz, Germany). 
 
For production of large amounts of plasmid DNA, the whole procedure was 
up-scaled by using the QIAGEN Plasmid Maxi Kit (Qiagen).  
 
3.7.4 Production of HIV-1 pseudotype stocks  
For pseudo-typed virus generation, wild type or mutated pTN7-Stopp 
plasmids were co-transfected with the pEnv035x (a specific plasmid 
expressing a CCR5-tropic HIV-1 envelope gene) into the 293T cell line. 
Briefly, 293T cells (106 cells) were transfected with 4 µg of each plasmid 
DNA using Lipofectamine-2000 (Invitrogen). 48 hours after transfection, 
virus-containing supernatants were harvested and filtered with 0.45 µm 
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cellulose-acetate filters (Schleicher & Schuell). Virus stocks were titrated, 
assayed for p24 levels and stored in 1 ml aliquots at - 80°C until use.  
 
3.7.4.1 Transfection of plasmids and collection of virus stocks 
Mix (for each sample) 
Solution 1 
pTN7-Stopp    3 µg 
pEnv035x   3 µg 
Optimem (Invitrogen)  up to 50µl 
Solution 2 
Lipofectamine-2000   2 µl 
Optimem (Invitrogen)  up to 50 µl 
 
Procedure: 
- 293T cell cultures from 50 ml culture flasks were washed. Cells were 
counted and plated in 10 cm culture dishes at a density of 106 cells/dish with 
10 ml of fresh DMEM medium. 
- Solution 1 and Solution 2 were incubated separately for 5 min at room 
temperature (one tube of Solution 1 was left without plasmids and used as a 
transfection control). 
- Both solutions were combined, gently mixed and incubated for 20 min at 
room temperature to allow plasmid-lipofectamine complexes to form. 
- The 100 µl mixture was then added to each plate one drop at the time in a 
clock-wise manner.  
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- The transfected dishes were cultured for 48 hours at 37oC in a CO2 culture 
chamber. 
- Supernatant of transfected cells was carefully removed with a 10ml sterile 
syringe and filtered with 0.45 µm filters into 15 ml falcon tubes. 1ml aliquots 
of each supernatant were transferred to 1.5 ml cryotubes and stored at -
800C. 
- The remaining cell monolayer of each dish was washed twice with 2-3 ml 
PBS and assayed for Renilla luciferase expression inside the cells (See 
Section 2.9) 
 
3.7.4.2 Titration of HIV-1 pseudoviruses with TZM-bl cells 
TCID50/ml: 
The titer, or TCID50/ml, of an HIV stock indicates the number of infective 
doses per ml, not the number of virus particles per se. While the total amount 
of virus in a stock can be measured by a p24 ELISA, the titration assay 
quantitates infection competent viruses. For titrations, virus stocks were 
serially diluted in a 96-well plate with the indicator cell line TZM-bl in triplicate 
for each dilution. The TCID50/ml of each stock is calculated using the dilution 
point at which 50 % of the cultures are infected.  
MOI: 
The multiplicity of infection, or MOI, refers to the amount of infective doses 
used relative to the number of target cells being infected. The MOI is 
adjusted according to experimental conditions. For example, if the chosen 
MOI is 0.01 and a total of 5x106 target cells are used, 5x104 cells will initially 
be infected. Then, if the titer of the virus stock is 1x106 per ml, or 1x103 per 
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µl, one would need 50 µl to infect the 5x106 cells at a final MOI of 0.01. 
 
Titration of virus stocks was performed by the dilution method with the TZM-
bl indicator cell line as target cells and by using the Britelite Luminescence 
Reporter Gene Assay System (PerkinElmer, #6016979) for quantification of 
luciferase expression. Prior to the titration procedure, one vial of lyophilized 
Britelite Substrate Solution was reconstituted with 250 ml of Britelite Buffer 
Solution. After the substrate was dissolved, the solution was distributed into 
15 ml conical polypropylene tubes and stored at -800C.  
 
Procedure (for two virus stocks) 
Day 1                                  
- 100 µl of DMEM medium was pipetted in all wells of a 96-well flat-bottom 
culture plate. 
- 25 µl of virus stock 1 was transferred to each well of the column 1, from 
wells A to D of the 96-well plate. 
- 25 µl of virus stock 2 was transferred to each well of column 1, from wells E 
to H of the 96-well plate. 
- 5-fold serial dilutions were made by mixing and transferring 25 µl of each 
well from column 1 to column 11. 25 µl from column 11 was discarded and 
column 12 was left untreated as control.  
- 1x104 TZM-bl cells in 100 µl medium containing 15 µg DEAE dextran/ml (30 
µl per 10 ml = 33 µl per 11 ml) was added to each well and the plate was 
incubated for 48 hours at 37°C  in a 5 % CO2 incubator. 
Day 3  
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- 100 µl of culture medium was removed form each well and 100 µl of the 
Britelite reagent solution was added to each well. 
- After 2 min incubation at room temperature, the contents of each well were 
mixed several times and 150 µl were transferred to a 96-well white plate for 
luminescence measurement.  
- Each plate was read in an automated luminometer (PerkinElmer) at an 
exposure of 1 sec/well, maximum 10 min after addition of the Britelite 
reagent. 
-The raw luciferase values were used to calculate the TCID50/ml according 
to the method of Reed and Muench using an excel-macro data sheet 
(provided by Dr. Steffi Link at the Fraunhofer-Institut IBMT, St. Ingbert, 
Saarland). 
 
3.7.4.3 p24 quantification 
Virus stocks were tested for the amount of p24 levels in the transfected 
supernatant. Even when the amount of p24 in the supernatant cannot 
indicate the viability of a virus, it gives an idea of the amount of viral particles 
present in the supernatant. Therefore, the p24 values can also be used to 
normalize infections. The amount of p24 in the virus stocks was quantified 
using a standard p24-antigen ELISA diagnostic kit (PerkinElmer). The kit 
provides reagents for immune complex disruption of antigen/antibody 
complexes in samples using a combination of low pH and heat. The samples 
are neutralized and transferred to a microplate. The captured antigen is 
complexed with biotinylated polyclonal antibody to HIV-1 p24, followed by a 
streptavidin-HRP (horseradish peroxidase) conjugate. The resulting complex 
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is detected by incubation with ortho-phenylenediamine-HCl, which produces 
a yellow color that is directly proportional to the amount of HIV-1 p24 
captured. The absorbance of each microplate well was determined by using 
a microplate reader calibrated against the absorbance of an HIV-1 standard 
curve.  
(PerkinElmer: 
http//las.perkinelmer.com/content/Manuals/MAN_HIV1p24ELISA.pdf) 
 
3.8 Antiviral drugs  
3.8.1 Zidovudine (AZT, Sigma).  
Zidovudine or azidothymidine (AZT) is a thymidine analog reverse 
transcriptase inhibitor (NRTI). NRTIs are deoxynucleoside triphosphate 
analogs, but lack a free 3'-hydroxyl group. When taken up by cells, AZT is 
phosporylated by thymidine kinases to the active AZT-triphosphate. Once 
AZT is incorporated into the nascent viral DNA, in a reaction catalyzed by 
HIV-1 reverse transcriptase (RT), further RT-dependent chain elongation is 
stopped due to the 3´azido-group (Sluis-Cremer, Arion et al. 2000). AZT was 
the first approved antiviral drug for treatment of HIV infection.  
 
3.8.2 Enfuvirtide (T20, Roche) 
Enfuvirtide (T20) is a synthetic 36-amino-acid oligopeptide fusion inhibitor 
belonging to the broader group of antiretroviral agents known as entry 
inhibitors. After binding of virus particles to the CD4 receptor on T 
lymphocytes and monocytes, molecular rearrangements in the 
transmembrane subunit of the HIV-1 envelope glycoprotein (gp41) result in 
 66 
fusion of the virus and cell membranes. These rearrangements involve the 
association of two helically coiled heptad repeats (HR-1 and HR-2) located in 
the ectodomain of the trimeric gp41 complex in the gp41 ectodomain. T20 is 
derived from HR-2 and corresponds to amino acids 127 to 162 of gp41 (Wild, 
Shugars et al. 1994). Binding of T20 to the trimeric HR-1 complex prevents 
the association of HR-1 with HR-2, thereby inhibiting fusion and blocking 
virus entry. 
 
3.8.3 Range of drug concentrations 
For the infection experiments, azidothymidine (AZT, Sigma) was used at final 
concentrations of 0, 0.03, 0.3, 0.1, 0.5, 1, 2, 2.5, 5 and 10 µM for the infection 
experiments. These cover the physiological concentrations of anti-retroviral 
therapy (Slusher, Kuwahara et al. 1992; Fletcher, Kawle et al. 2000). The 
HIV-1 entry-inhibitor Enfurtivide (T20) was used at final concentrations of 
0.08, 0.1, 0.5, 0.8, 2.5 and 10 µg/ml (Neumann, Hagmann et al. 2005).  
 
3.9 Pseudotype infections and determination of relative fitness 
Target cells for infection experiments were peripheral blood mononuclear 
cells (PBMC) from healthy blood donors and TZM-bl cells. Cells were 
cultured overnight and the next day plated in triplicate or quadruple on 96-
well V-bottom plates (Greiner) at a density of 105 cells/well. Cells were left 
untreated (0 µM AZT or 0 µg/ml T20 for the phenotypic mixing experiments) 
or pre-incubated for 2 hours before infections with drugs at the final 
concentrations mentioned in section 2.8.3. PBMC from healthy donors were 
stimulated overnight with Phytohaemagglutinin (PHA, Difco) at a 
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concentration of 2.5 µg/ml prior to the drug incubation. Infections were 
performed for each drug treatment by adding wild type and mutant virus at an 
MOI of 0.5 in 100 µl of medium to untreated or treated cells for each well. 
Forty-eight hours after infection, cells were washed and assayed for 
luciferase activity with the Renilla Luciferase Assay System Kit (Promega) 
(see Section 2.10). The measured luciferase activities from infections were 
normalized to the transfection efficiencies of 293T cells during HIV 
pseudotype preparation and/or to the p24 levels of the corresponding viral 
stocks. The final relative fitness values for all HIV AZT-resistant variants 
were obtained by relating them to the fitness of the wild type (see 2.11 
Statistical analysis). This approach was also followed in the phenotypic 
mixing experiments. 
 
3.10 Renilla Luciferase Assay  
Renilla luciferase is a monomeric 36 kDa protein, which catalyzes the 
oxidation of coelenterate-luciferin (coelenterazine) to produce light 
emissions. Post-translational modification is not required for its activity; 
therefore the enzyme can function as a genetic reporter immediately 
following translation. The Renilla Luciferase Assay System from Promega 
(#E2820, #TM055, www.promega.com) is designed to provide a fast and 
sensitive method of detecting the luciferase from sea pansy (Renilla 
reniformis). It enables measurement of Renilla luciferase activity using either 
the wild type or new synthetic Renilla luciferase as a primary reporter to 
study replication and transcriptional regulation, or to normalize experimental 
variations such as differences in transfection efficiencies.  
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Product: 
Assay Substrate (100X)  1000 µl 
Assay Buffer   100 ml 
Assay Lysis Buffer (5X)  30 ml 
Storage at -200C 
 
Procedure: 
Before cell handling for luciferase measurements, one volume of the 100X 
Assay Substrate was added to 100 volumes of the Assay Buffer to produce 
the 1X Substrate Buffer Solution. Since this buffer is prepared fresh, the 
volume changed depending on the number of measurements performed that 
particular day.  
 
i) Transfections 
- After removing the culture medium, cells were treated briefly with PBS and 
the PBS discarded.  
- 1 ml of the Assay Lysis Buffer (1X, with distilled water) was added to each 
culture dish. After 5 min incubation, homogeneous lysates were prepared by 
manually scraping the cells from the culture dishes and transferring them to 
1.5 ml eppendorf tubes (Greiner). 
- A 96-well white plate was prepared by adding 50 µl of the 1X Substrate 
Buffer Solution to each well depending on the number of measurements to 
perform. 
- The lysates were cleared from cellular debris by a 30 sec centrifugation at 
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40C and 50 µl of each lysate was transferred to a 96-well white plate. 
- After gently mixing the contents in the wells and incubating the plate for 5  
min, the plate was placed in the automated luminometer and the light units 
measured at an exposure of 5 sec/well.  
 
ii) Infections: 
- 48 hours after infections, the 96-well V-Shape plates were centrifuged for 
5min at 1400 rpm. The cells remain at the bottom of the V-Shape well. 
- The culture medium from each well was carefully taken out, and 60 µl of the 
Assay Lysis Buffer (1X, with distilled water) was added to each well. 
- Each plate was incubated 10 min. During this period, a 96-well white plate 
was prepared by adding 50 µl of the 1X Substrate Buffer Solution to each 
well. 
- After the 10 min incubation, the contents of each well in the 96-well V-
Shape plates were mixed and 50 µl of the lysates were transferred to the 96-
well white plates. 
- After gently mixing the contents in the wells and incubating the plate for 5 
min, the plate was placed in the automated luminometer and the relative light 
units per second (RLU/s) measured at an exposure of 5 sec/well.  
 
3.11 Fitness estimations and statistical analysis 
The method of estimating the mean fitness value for every HIV pseudotype 
infection was performed as follows:  
(i) The mean value of a given number of independent measurements 
of RLU/s was estimated for each pseudotype (RLUpseudotype). 
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(ii) The mean background value, i.e. control (RLUcontrol) was used to 
correct the original value from the background by subtracting it, 
RLUcorrected=RLUpseudotype-(3xRLUcontrol). 
(iii) To normalize the corrected replication capacity, we used the 
transfection efficiency parameter, teff, thus getting absolute fitness 
estimate fabs=RLUcorrected/teff.  
(iv) Finally, the absolute fitness estimates were normalized with 
respect to the absolute fitness value of the wild type genome 
without drug (f0):  f = fabs/f0, giving the final relative fitness values.  
 
The above estimates of the mutant fitness by using the sample means 
were supplemented by evaluating their sample variances using the 
formulas for variances of the products and ratios of independent random 
variables (Armitage 2002). The donor cell data were used to estimate the 
mean fitness and variance values for each mutant using standard 
formulas for the mean and variance of the sum of independent random 
variables.  
To evaluate the epistasis values two different approaches were used. 
One is based upon a direct calculation of the mean and variance values 
using the epistasis formula (see Section 4, Results) and the rules for 
dealing with the functions of random variables (Armitage 2002). The 
second one implements a parametric bootstrap method to make inference 
about the mean and its associated standard error. To this end a normal 
distribution with the corresponding estimated sample mean and variance 
was used to draw the fitness values of wt, single- and double mutant 
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genomes with the size of the generated sample of 1000. The 95% 
confidence intervals were calculated using the bootstrap estimates of the 
standard deviation (SD) as mean± 1.96*SD (See Section 7 Appendix)   
 
The statistical analysis, epistasis calculations and the steady-state model 
presented in this thesis work was performed in collaboration with Prof. 
Gennady Bocharov and Anna Ignatovich from the Institute of Numerical 
Mathematics, Russian Academy of Sciences, Moscow, Russian 
Federation. 
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4. Results  
 
4.1 The fitness ranking of individual mutants drives patterns of epistatic 
interactions in HIV-1 
 
4.1.1 Selection of a HIV-1 mutation pathway for analysis of epistatic 
interactions.  
In order to measure the relative fitness of specific HIV variants, analyze 
epistatic effects and their dependence on environmental factors such as host 
cells and antiviral drugs, a specific mutational pathway that HIV-1 follows in 
vivo during treatment with azydothymidine (AZT) was chosen (Figure 12).  
 
AZT is the prototypic reverse transcriptase (RT) inhibitor first used in infected 
patients and is a common component of current anti-retroviral formulations. 
Once inside the cells, AZT is phosporylated by thymidine kinases to the 
active AZT-triphosphate. Upon incorporation into the growing HIV DNA 
strand, the RT-dependent chain elongation is stopped due to the 3´azido-
group (Sluis-Cremer, Arion et al. 2000). Treatment of HIV-infected individuals 
with AZT leads to the selection of AZT-resistant HIV-mutants with defined 
amino acid changes in the RT. The HIV-1 resistance pathway chosen is 
characterized by the key AZT-resistant mutations at positions 41 and 215 of 
the RT (Lacey and Larder 1994; Beerenwinkel, Daumer et al. 2005).  
 
Even when the mechanisms of resistance are not completely clear, 
biochemical studies have suggested a mechanism of AZT resistance 
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involving terminal AZT removal from the blocked primer strand in an ATP-
dependent pyrophosphorolysis reaction (Boyer, Sarafianos et al. 2001; 
Boyer, Sarafianos et al. 2002). This reaction might be enhanced by the 
T215Y mutation by promoting ATP binding (Boyer, Sarafianos et al. 2001). 
Contacts with the 215 side chain could be made via parallel aromatic ring 
stacking of the adenine base of ATP, forming a number of van der Waals 
contacts as has been suggested previously (Boyer, Sarafianos et al. 2001; 
Boyer, Sarafianos et al. 2002) (Boyer et al, 2001). Structural mechanisms 
whereby the M41L mutation could lead to increased ATP binding are less 
clear. The 41 residue is located some distance from the 215 residue and is 
somewhat buried, making direct interaction with ATP unlikely (Chamberlain, 
Ren et al. 2002). The M41L mutation introduces a branched side chain that 
potentially might disrupt this buried region. It thus seems more likely that a 
conformational rearrangement occurs either within the catalytic complex or 
on binding of ATP rather than that there are two distinct ATP binding 
positions, each of which is strengthened by the mutations at either residue 41 
or residue 215. The former model would be consistent with the strong effect 
of the combination of the M41L and T215Y mutations on AZT resistance. 
 
A schematic representation of the pathway is shown in Figure 12. The highly 
AZT-resistant double mutant M41L-T215Y appears in vivo after around 255 
weeks of treatment and requires a number of intermediate mutants of which 
only the M41L and T215Y mutants are commonly observed (Beerenwinkel, 
Daumer et al. 2005). However, at least one of the other possible 
 74 
intermediates, T215S, T215N, M41L-T215S and M41L-T215N must have 
been transiently generated (Figure 12, in grey). 
 
 
Figure 12. Mutation pathway of the HIV-1 reverse transcriptase under AZT therapy in 
vivo. The scheme shows one common in vivo developmental pathway of AZT-resistant HIV-
1 mutants at amino acid positions 41 and 215 in the reverse transcriptase. Amino acids are 
given in the one letter code. In the block arrow, estimated waiting times of mutant 
appearance are marked. The values are according to estimations from Beerenwinkel, et al. 
(Beerenwinkel, Daumer et al. 2005) The flowchart arrows highlight the respective nucleotide 
changes. Mutants commonly found in vivo are in bold type while mutants in grey are not 
observed in vivo or are rare. 
 
4.1.2 Generation of AZT-resistant mutants of HIV-1, fitness 
determination and epistasis calculations.  
All seven HIV-1 RT mutants from the AZT-resistance pathway (Figure 12) 
were generated by site-directed PCR and cloned into an HIV-1 NL4-3-based 
vector that is deficient in the expression of a functional envelope (Env) 
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protein and contains the Renilla luciferase gene in the position of nef 
(Neumann, Hagmann et al. 2005). Respective HIV-1 Env-pseudotyped 
viruses that can only undergo a single round of infection in susceptible target 
cells were subsequently produced from 293T cells after co-transfection with 
RT mutants and an HIV-1 env expression plasmid. The relative fitness of the 
mutant viruses was assessed under a range of physiologically relevant AZT 
concentrations by infecting the TZM-bl cell-line or primary peripheral blood 
lymphocytes (PBMCs) from two healthy donors (here referred to as Donors 1 
and 2) and measuring the relative luciferase activities of the variants 
compared to that of the wild-type (Materials and Methods). The epistatic 
interaction E of the mutations was then calculated according to the epistasis 
definition in a two-locus-two-allele model. In the context of this work, the term 
locus refers to a mutant site in the HIV genome that confers drug resistance. 
The two alleles represent drug sensitivity (wild type) or drug resistance 
(mutant) depending on the mutations at each locus. With two loci and two 
alleles coding for drug sensitivity, there are four types of viruses which are 
fully sensitive, partially resistant and fully resistant.  Under this conditions, 
epistasis (E) is calculated with the formula:  
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 [Equation 1], 
 
where 
! 
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00  is the fitness of fully sensitive virus (the wild type), 
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of the double mutant and 
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 are the fitness of both single mutants, 
respectively.  
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A visual approach to estimate positive or negative epistasis is by plotting the 
fitness measured experimentally against the expected fitness calculated 
based on the assumption of no epistatic interactions (van Opijnen, Boerlijst et 
al. 2006; Kouyos, Silander et al. 2007). This is done by multiplying the fitness 
of the single mutants and graphically comparing the resulting fitness with the 
fitness of the double mutants.  
 
4.1.3 The fitness ranking of AZT-resistant HIV-1 RT mutants 
corresponds to their frequency distribution in AZT-treated patients.  
The distribution of fitness relative to that of the wild type for all single and 
two-point HIV-1 RT mutants infecting TZM-bl cells or PBMC in the presence 
of 0 to 10 µM AZT is shown in Figure 13 and the respective values are given 
in Table A1 in the Appendix. With the TZM-bl cell line and the PBMC of these 
two blood donors as target cells, the wild-type virus has a varying fitness 
advantage over the AZT-resistant variants in the absence of drug. Increasing 
drug concentrations render particularly the mutants M41L, T215Y and 
M41L/T215Y more fit than the wild type. These dominant RT mutants have 
been analyzed previously and the determined relative fitness values are 
concordant with previous findings (Harrigan, Bloor et al. 1998; Wang, Mittler 
et al. 2006). Similarly concordant are the inhibitory concentration 50 (IC50) 
values for AZT that have been determined for these mutants (Richman, Shih 
et al. 1991; Arts, Quinones-Mateu et al. 1998; Harrigan, Bloor et al. 1998; 
Maeda, Venzon et al. 1998; Petropoulos, Parkin et al. 2000) and which can 
be derived from these fitness measurements as a function of drug 
concentrations. The newly analyzed intermediate mutants T215S, T215N, 
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M41L-T215S and M41L-T215N of the AZT-resistance pathway exhibit low 
fitness values under all drug concentrations with the 215S mutants being 
slightly fitter than the 215N. Thus, taken together, the ranking order of the 
fitness values for all RT mutants in the presence of AZT correspond well with 
the frequency distribution of the respective mutants found in patients under 
AZT treatment i.e. T215Y > M41L > T215S > T215N (Stanford Drug 
Resistance Database, http://hivdb.stanford.edu). 
 
The fine structure of the fitness distribution of the RT mutants in TZM-bl and 
PBMC revealed interesting features. First, the relative fitness of the AZT-
resistant mutants is influenced by the host-cell environment. For example, 
the mutants T215Y and M41L-T215Y exhibit a higher relative fitness without 
drug in PBMC of donor 2 than in PBMC of donor 1 or TZM-bl cells. 
Furthermore, with the exception of the M41L-T215S, the non-dominant RT 
mutants are fitter in TZM-bl cells under all AZT concentrations than in PBMC. 
Second, the fitness of the wild type in the presence of AZT is usually higher 
in PBMC than in TZM-bl cells. This mounts to an about 10-fold and 30-fold 
difference under 2 µM and 5 µM AZT respectively. Under 10µM AZT, the 
replication of the wild type was practically not detectable in all cell-types. 
Third, the fitness differences between the wild type and the RT mutants are 
not constant. For example, with 5 µM AZT, the highly resistant mutant 
M41L/T215Y exhibits a 160-fold higher fitness than the wild type in TZM-bl 
cells but is only around 6-fold or 20-fold fitter in PBMC of donor 1 and 2, 
respectively. Thus, the fitness behavior of the wild type and the RT mutants 
as a function of AZT concentrations is cell type dependent. This correlates 
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well with the observation that HIV replication and adaptation strongly 
depends on the host-cell environment (Arts and Wainberg 1994; Arts, Marois 
et al. 1996; van Opijnen, de Ronde et al. 2007).  
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4.1.4 The HIV-1 AZT-resistance pathway is characterized by strong and 
varying epistasis between the RT mutations at amino acids 41 and 215.  
In order to analyze possible interactions between the mutations of the key 
amino acids along the AZT-resistance pathway, epistasis (E) was calculated 
from the determined fitness values according to equation 1. Without drug 
pressure, E is always strongly positive for the TZM-bl cells and both PBMC 
Donors (Table A2 in Appendix) however the relative values for the three 
double mutants differ in the target cells. To better visualize the epistatic 
interactions between all RT mutations, the experimental fitness values of the 
double mutants (i.e. the observed fitness) were plotted against the products 
of the fitness of the one-point mutants (i.e. the expected fitness under the 
assumption of no epistatic interactions) (Figure 14A). Positive epistasis 
means that the fitness of the double mutants is higher than expected (the 
diagonal line corresponds to no epistatic effects). To test whether the overall 
finding of epistatic interactions is statistically robust, we performed 
bootstrapping to generate randomized data sets (N=1000) and applied the 
same analysis. In all cases the mean epistasis values were significantly 
greater than zero (Table A2 in Appendix).  
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4.1.5. The epistatic interactions between the mutations changed upon 
increasing drug pressure and differed between the target cells used.  
An increase in AZT concentrations resulted in a decrease of epistasis. The 
three different double mutants showed a varying relative decrease in the 
different target cells. With TZM-bl cells, the sign of epistasis changed to 
negative already from the lowest AZT concentration whereas with the PBMC 
of donors 1 and 2, epistasis was mainly (donor 1) or always (donor 2) 
positive (Figure 14B). The change in the sign of epistasis in the TZM-bl cells 
is mainly due to the fitness ranking of the wild type, which is relatively low, 
and the 1-point mutants, which are relatively high in these cells as compared 
to PBMC (Figure A1). Together these observations show that the type of 
fitness interaction may change along with the environmental conditions under 
which it is analyzed. In the absence of drug, the fitness loss due to the 
acquisition of resistance mutations is compensated by a strong antagonistic 
interaction (positive epistasis) in all cases. However when AZT is present, 
the fitness interaction is still antagonistic (now negative epistasis) in TZM-bl 
cells but becomes mainly synergistic (now positive epistasis) in PBMC. Thus 
the fitness gain is less than expected for TZM-bl cells but mainly higher than 
expected for PBMC.  
 
4.1.6 Epistasis affects the relative abundance of drug-resistant HIV-1 
mutants.  
The fitness interactions between the mutations along a drug-resistance 
pathway are expected to have an impact on the relative mutant frequencies 
in a viral population. This in turn may be of great clinical importance for the 
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selection of drug-resistance under antiviral treatment because a higher or 
lower steady state level of a resistant mutant may lead to a faster or slower 
outgrowth. Having determined all fitness values for all mutants along the 
AZT-resistance pathway, a quantitatively estimate of the effect of epistasis 
on the relative abundance of the double mutants was performed. For this, the 
expected fitness values under the assumption of no epistasis were calculated 
from the experimentally determined fitness values and used to analyze the 
respective steady state frequencies assuming a mutation-selection 
equilibrium as defined by the general model of HIV quasispecies dynamics 
(Nowak 2000). Under this condition, the relative abundance of the wild-type 
virus and the 1-point and 2-point mutants can be estimated by computing the 
eigenvectors of the following eigenvalue problem [Equation 2]: 
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Here,
00
y and 
11
y denote the equilibrium abundance of the wild-type virus and 
the 2-point mutant, respectively, whereas 
01
y  and 
10
y  denote the equilibrium 
abundance of the 1-point mutants. The parameters 
1
µ  and 
2
µ  characterize 
the mutation rate for the first position and for the second position 
respectively. Under the simplifying assumption that the mutation rate 
! 
µ is not 
affected by the mutations itself, the relative frequencies of the 2-point 
mutants can be readily calculated using our fitness data (Table A1) and 
MATLAB routines (www.mathworks.com). The results are shown in Figure 15 
and Table A3.  
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Depending on the AZT concentration, the presence of epistasis has a 
marginal or a significant effect on the relative frequency distribution of the 2-
point mutants within the virus population. Importantly, high epistasis values 
do not directly predict a large effect on that distribution. For example, without 
AZT when epistasis is highest, the relative mutant frequencies are around 10-
8 to 10-9 and epistasis affect that frequencies up to 3-fold (Figure 15 and 
Table A3). In the presence of AZT when epistasis values were significantly 
smaller, frequency effects of up to around 10,000-fold are observed. Taking 
the M41L/T215Y mutant in the presence of 0.03 µM AZT as an example, 
epistasis increased the relative frequency around 10,000-fold according to 
the measurements in PBMC of donor 2 (Table A3c), diminished it around 
10,000-fold according to the measurements in TZM-bl (Table A3a) or left it 
relatively unchanged (PBMC donor 1, Table A3b). Furthermore, the 
frequency effects were not linear. Taking again the M41L/T215Y mutant, 
epistasis increased the relative frequency around 10,000-fold at 0.03 µM AZT 
and 2 µM AZT, however had nearly no effect at 0.3 µM AZT. This complex 
behavior is due to the fact that the epistasis effect on mutant frequencies 
strongly depends on the distribution of the relative fitness values for wild 
type, intermediate mutants and the 2-point mutant, i.e their ranking.  
 
If the intermediate one-point mutants (at least one of them) have larger 
fitness value than the two-point mutant would have in the absence of 
epistasis then the effect would be strong. Otherwise the two-point mutant will 
be dominating with and without epistasis. Let us consider two examples: 
Under 0.3µM AZT in PBMC of donor 2, the fitness values for wild type, M41L, 
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T215Y and M41L-T251Y are 0.162, 0.166, 0.293 and 0.385, respectively 
(Table A1c). Thus, one would expect that the M41L-T251Y mutant will be 
dominating because of its highest fitness and its relative frequency is 
expected to be close to 1 (in fact 0.999; Table A3c). Assuming no epistatic 
interaction, the relative fitness for the same variants are 0.162, 0.166, 0.293 
and 0.300, respectively. Again the M41L-T251Y mutant remains to be 
dominating because it has the highest fitness and its relative frequency is 
close to 1 (0.998). In the case of 2 µM AZT, the fitness values with epistasis 
are 0.0426, 0.0236, 0.116 and 0.187, respectively. The M41L-T251Y mutant 
will be dominating with a relative frequency close to 1 (in fact 0.999). 
Assuming no epistasis, the relative fitness is 0.0426, 0.0236, 0.116 and 
0.0642, respectively. Now the 1-point T251Y mutant will be dominating 
because it has the highest fitness and its relative frequency is expected to be 
close to 1. In this case the relative frequency of the two point mutant M41L-
T251Y is only 0.0000897. Thus the epistatic effect is large although the 
epistasis value is small (Figure 14B). 
 
4.2 Phenotypic mixing modulates the infectivity and fitness of HIV drug-
resistant variants.  
 
4.2.1 Selection of variants for the analysis of phenotypic mixing effects 
To address whether HIV variants phenotypically mixed with wild type and 
AZT-resistant RT may impact fitness of phenotypically variants, mutations 
M41L, T215Y and the double mutant M41L-T215Y from the AZT-resistant 
pathway were chosen. 22 different pseudotypes that carry up to 1:4 ratios of 
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wild type and drug-resistant RT were produced. Another set of 5 different 
pseudotypes contained a mix of wild type and Enfuvirtide (T20)-resistant 
envelope proteins, and a set of 4 pesudotypes were produced with a mix of 
wild type and mutant RT and envelope proteins. (See Materials and 
Methods).  
 
4.2.2 The fitness change of virions carrying mixed RTases is gradual 
and in-between the pure phenotypes  
The comparative distribution of fitness for all phenotypically mixed variants 
infecting PBMC in the presence of 0 to 10 µM AZT is shown in Figure 16.  
Fitness values are related to the fitness of the virion carrying all copies of 
wild type RT (here referred as «100% wild type»). Overall, the fitness of the 
phenotypically mixed pseudotypes was in between the pure virions (i.e. the 
virions carrying 100% of the wild type or 100% of the mutant RT), and the 
decline in the fitness without drug (or the increase with drug) was rather 
gradual as the % of mutant RT inside the virions increased (Figure 16). 
  
Without the addition of drug, the wild type has a fitness advantage over all 
the phenotypically mixed variants. Interestingly, with already 25% of the 
M41L RT, the fitness was reduced to only a 50% of the pure wild type. 
(Figure 16, upper left). This initial decrease in fitness was not changed as the 
amount of M41L RTases inside the virion increased. It was previously 
estimated that each HIV-1 virion contains about 50 RT molecules (Coffin 
1979). Thus the inclusion of around of around 25% or 10 to 12 molecules of 
the RT carrying the M41L mutation is sufficient to lower the fitness similar to 
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the variant carrying all copies of the M41L RT. Mixing copies of wild-type and 
the T215Y or the M41L-T215Y mutant RTases showed a decrease in fitness 
which was proportional to the increase of the number of mutant RT inside the 
virion (Figure 16, second and third group). The decrease in fitness shown by 
these intermediates was not significant until 50 to 75% copies of these 
mutant RT were present inside the virions, contrasting with the fitness 
behavior observed in the wild type - M41L mixes (see Discussion). The 
fitness of pseudotypes mixed solely with the M41L, T215Y and the M41L-
T215Y resistant RT did not significantly differ from the fitness of the pure 
phenotypes as shown by the standard errors of the mean (Figure 16, upper 
left). 
 
Upon addition of AZT, the phenotypically mixed variants exhibit higher 
relative fitness than the one carrying all copies of the wild type RT. With the 
exception of the mix wild type plus the M41L, which under 1 and 2 µM AZT 
decreased the fitness of the intermediate pseudotypes, all virions carrying at 
least 25% of mutant RTases showed a higher relative fitness than the wild 
type under the whole range of AZT concentrations (Figure 16). This fitness 
difference was larger as the concentrations of the drug increased and again 
gradual between the extremes.  Similar to what is shown in the previous 
fitness analysis, only virions carrying 75 to 100% of the highly resistant 
T215Y and M41L-T215Y RTases replicate efficiently under high 
concentrations of drug.  
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4.2.3 Incorporation of Enfuvirtide (T20)-resistant envelope proteins do 
not affect trimer function but alter the infectivity of phenotypically 
mixed virions.  
HIV envelope proteins arrange in trimers on the virion surface (Liu, 
Bartesaghi et al. 2008). Envelope binding to the CD4 receptor results in a 
major reorganization of the Env trimer, causing an outward rotation and 
displacement of each gp120 monomer. This is followed by a rearrangement 
of the gp41 region along the central axis of the trimer, leading to a closer 
contact between the viral and target cell membranes (Liu, Bartesaghi et al. 
2008). Enfuvirtide (T20) binds to the gp41 and prevents viral entry by 
blocking the conformational change needed for fusion. If binding of 
Enfuvirtide to a single gp41 molecule in the trimer would be sufficient to block 
its function, heterotrimers consisting of a mix of sensitive and T20-resistant 
(T20Res) monomers should be blocked at approximately the same IC50 as 
homotrimers (C. Jassoy, unpublished data).  
 
In order to analyze the effect of phenotypic mixing on HIV infectivity and 
trimer function, a set of five pseudotypes was produced. These included 
virions carrying a ratio of up to 1:4 mixes of wild type and T20Res envelopes 
(i.e. virions carrying 100% of the wild type envelope in its surface, 75% of 
wild type plus 25% T20Res, 50% of both and 25% wild type plus 75% of 
T20Res). Figure 17 shows the relative infectivity of all variants in PBMC from 
two different donors (Donors 4 and 5) without T20 and under increasing 
concentrations of the drug. T20 decreased the infectivity of the fully sensitive 
pseudotype (i.e. the 100% wild type virus) in a dose-dependent manner. The 
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IC50 for T20 in these cells was between 0.08 and 1 µg/ml of T20 for the fully 
sensitive variant (100% wild type) (Figure 17A, upper left), whereas in cells 
from Donor 4, the T20 IC50 for the pseudotypes carrying 50% of resistant 
envelopes was 0.4 µg/ml of T20. This is in the range of the T20 IC50 for HIV-1 
isolates using CCR5 as correceptor in vivo (Derdeyn, Decker et al. 2000). 
Interestingly, the low infectivity (around 10%) exhibited by the fully resistant 
pseudotype (the 100% T20Res) without drug remained mostly constant until 
concentrations of 2 µg/ml of T20. Under concentrations of 10 µg/ml of the 
drug, the 100% wild type pseudotype was completely blocked and the 
infectivity of the 100%-T20Res was reduced by 50% (Figure 17B). The 
infectivity of the intermediate variants was, as with the phenotypically mixed 
RTases, in between the pure pseudotypes. 
 
The gradual decline in relative infectivity, and the observation that 
pseudovirions containing different ratios of both sensitive and resistant 
glycoproteins were only slightly less sensitive to enfuvirtide than the fully 
resistant pseudovirions (as shown by the change in the IC50), suggests that 
heterotrimers formed with wild type and T20-resistant glycoproteins are not 
completely blocked by enfuvirtide. This is in agreement with similar data 
obtained by Prof. Christian Jassoy, Leipzig (personal communication). 
However, these observations may be insufficient to make further 
assumptions on trimer function. For instance, it is yet not clear how many 
trimers HIV carries in its viral membrane, and how many are needed to 
succesfully infect a cell. The literature is inconclusive in this respect. 
Recently, mathematical models on the stoichiometry of HIV entry suggested 
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that a minimum of 8 trimers are needed for infection (Magnus, Rusert et al. 
2009), whereas electron tomography analysis has suggested that around 5 
to 7 envelope trimers cluster at the virion-cell interface (Sougrat, Bartesaghi 
et al. 2007).  The number of those that interact with the CD4 receptor is not 
known. Nevertheless, the data shown in this thesis work suggest that the 
phenotypic mixing of wild type and low-infectivity drug-resistant envelope 
proteins does not alter the trimer function.  
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Figure 17. Phenotypic mixing of glycoproteins alter the infectivity HIV variants in a 
dose-dependent manner. Bar-plot of the relative infectivity (as the % of infected cells) in 
PBMC from two donors for the five phenotypically mixed HIV pseudotypes and under 
increasing concentrations of T20. The graph is divided in four panels for better visualization 
of the data. A) Infectivity under the range of 0 to 0.4µg/ml T20. B) Infectivity under 2 and 10 
µg/ml T20. Error bars are standard errors of the mean. 
 
4.2.4 AZT and T20 in combination altered the fitness distribution of 
phenotypically mixed double-resistance variants  
In order to analyze the effect of phenotypic mixing on fitness under the 
combination of two antiviral drugs, pseudotypes carrying wild type and the 
AZT-resistant T215Y RTases were produced together with mixes of wild-type 
and T20-resistant envelopes (T20Res). Infections were performed in PBMC 
from two donors (Donors 6 and 7) without drug and under concentrations of 
both drugs combined.   
 
Figure 18 shows the mean relative fitness distribution for all variants infecting 
PBMC under 0 to 10µM AZT in combination with T20 at the same 
concentrations. Overall, the phenotypically mixed variants exhibit a slightly 
higher replication capacity in cells from Donor 6 than in cells from Donor 7. 
Without the addition of drugs, the variant carrying both wild type RTases and 
envelopes has the fitness advantage over the intermediate ones, which as 
seen in sections 4.2.2 and 4.2.3, show a fitness decrease that is in between 
the pure pseudotypes. Interestingly, the intermediate variants carrying either 
resistant RT or resistant envelopes in combination with the wild type (WT RT-
T20Res ENV or T215Y RT-WT ENV) showed a similar relative fitness, 
indicating that the inclusion of the wild type into the virion compensates 
equally to the fitness loss introduced by the mutants (Figure 18A).  
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Figure 18. Relative fitness of variants carrying a combination of drug resistant 
RTases  and Envelope proteins. Bar-plot of the relative fitness in PBMC from two 
donors for the phenotypically mixed HIV pseudotypes and under increasing 
concentrations of AZT and T20. The graph is divided into four panels for better 
visualization of the data. A) Fitness under 0 and 0.1µM AZT plus 0.1µg/ml T20. B) 
Fitness under 0.5, 2.5 and 10 µM AZT plus 10µg/ml T20. Error bars are standard 
errors of the mean. 
 
AZT and T20 in combination altered the fitness distribution of the 
phenotypically mixed pseudotypes. Increasing concentrations of the drugs 
render the T215Y RT-T20Res ENV more fit. Under 10 µM AZT in combination 
with 10 µg/ml T20 it is the only variant still replicating (Figure 18B). Of 
interest was the observation that in both donors, virions carrying the T20Res 
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ENV exhibited higher relative fitness independent of the RT phenotype that it 
carried. Under 0.5 µM AZT and 0.5 µg/ml T20, the difference in fitness 
favoring the WT RT-T20Res ENV over the T215Y RT-WT ENV phenotype was 
50% (Figure 18B). It appears that, with the addition of drugs, the 
counterweight effect provided by the respective mutant phenotype (as 
observed without drug pressure) does no longer help to compensate for the 
fitness loss and the pseudotypes carrying the T20Res envelope have the 
fitness advantage irrespective of the RT phenotype, probably due to their 
ability to enter the cell more efficiently.  
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5. Discussion  
5.1 On the impact of epistatic interactions in HIV 
Epistasis is a fundamental component of the genetic architecture of biological 
entities and has been suggested to play a main role in the evolutionary 
dynamics of virus populations (Michalakis and Roze 2004; Sanjuan, Moya et 
al. 2004; Bellew and Chang 2006; Elena, Carrasco et al. 2006). Epistatic 
interactions were found to be present in many diverse DNA and RNA viruses 
(Crotty, Cameron et al. 2001; You and Yin 2002; Burch and Chao 2004; 
Sanjuan, Moya et al. 2004; Silander, Tenaillon et al. 2007; Tsetsarkin, 
McGee et al. 2009), and  a wide range of mutational interactions (positive 
and negative) was observed. Epistatic interactions may directly impact viral 
robustness and the efficiency of variant selection under therapy (Sanjuan, 
Moya et al. 2004; Elena, Carrasco et al. 2006; Kouyos, Silander et al. 2007; 
Rolland, Brander et al. 2007; Elena, Sole et al. 2010). 
 
Due to its genetic diversity, established in vitro assays, in silico models and 
the availability of large amounts of in vivo data from infected patients, HIV is 
an ideal candidate to study fitness interactions. In this thesis work, the fitness 
of all HIV-1 mutants along the classical 215-41 AZT-resistance pathway was 
quantified under physiological concentrations of the drug ex vivo, and the 
values of the fitness interactions between the mutations were calculated and 
used to estimate the impact of epistasis on the relative mutant frequencies 
within the viral population. Overall, the pattern of epistasis was complex and 
dependent on the drug concentrations and the host cells used. Without AZT, 
epistasis was consistently positive within the TZM-bl cell line and the PBMC 
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of both of the blood donors tested, and resulted in an estimated 1.5 to 2.8-
fold increase in the ratio of the highly resistant 2-point mutant M41L-T251Y to 
wild type (Figure 15). The presence of environmental pressure (in the form of 
physiological concentrations of AZT) leads to a concentration-dependent 
decrease in the strength of the epistatic interactions (Figure 14). The sign 
and the size of epistasis differ between the host cells used and the numerical 
values did not predict the epistatic effect on the mutant frequency. This 
complex behavior is explained by the fitness ranking of all mutants in the 
presence of AZT and the uneven fitness distribution of the 1-point mutants 
between the target cells. 
 
The observed positive epistasis under drug-free conditions has a buffering 
effect on the mutant distribution and caused an increase of the relative 
frequency of the highly AZT-resistant 2-point mutant M41L-T251Y over the 
expected frequency if epistasis would be absent. However this relative 
frequency increase from about 1x10-8 to about 3.6x10-8 (Table A3) within the 
virus population is only marginal considering an estimated effective 
population size of HIV in vivo of around 103 to 104 (Althaus and Bonhoeffer 
2005). In the presence of AZT, the sign of epistasis varies with the drug 
concentrations and the host cells used. As a consequence, epistasis 
increases or decreases the relative 2-point mutant frequencies or leaves it 
relatively unchanged. For example, under 0.03µM AZT and TZM-bl as host 
cells, epistasis decreases the relative frequency of M41L-T215Y from 1 to 
5.5x10-4, whereas with PBMC from Donor 2, epistasis increases the relative 
frequency from 4.5x10-4 to almost 1 (Figure 15). Although these estimated 
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relative frequencies under drug pressure are now in the range of the effective 
population size of HIV in vivo (a condition where epistatic effects are 
expected to be relevant), the variable and complex pattern of fitness 
interactions and their dependence on specific environmental conditions, 
suggests that there are no consistent experimental criteria to derive general 
statements on the importance of the epistatic effects for the mutant 
frequency at the population level.  
 
Epistasis was suggested to possibly contribute to viral robustness, the ability 
of a virus to maintain stable functioning despite genetic and environmental 
perturbations (Sanjuan, Forment et al. 2006; Elena, Sole et al. 2010). In 
general, single mutations in a viral genome are naturally deleterious, 
reducing the fitness of the virus. If the deleterious effects of the mutations are 
strong enough, those variants might be lost rapidly and the population forced 
to cluster in reduced and narrow peaks of the adaptive fitness landscape 
(Elena, Carrasco et al. 2006). The observed predominance of positive 
epistasis among viral genomes suggests a buffering effect as subsequent 
mutations occur, such that the mutant spectrum is enlarged (Montville, 
Froissart et al. 2005; Kouyos, Otto et al. 2006; Sanjuan, Forment et al. 2006). 
This in turn may become beneficial for the virus population in the context of a 
strong selection pressure like antiviral treatment. However ,as shown in this 
thesis work, for the mutants along the AZT resistance pathway, the buffering 
effect without AZT is so low that positive epistasis is unlikely to be a major 
contributing factor to the robustness of HIV i.e. to allow low fitness mutants to 
survive in an HIV population in vivo, and thus, making the adaptive fitness 
 98 
landscape flatter. Therefore, other mechanisms than epistasis may be 
considered as of prime importance within infected individuals to contribute to 
HIV robustness. First, the HIV provirus can persist for months independent of 
the replicative capacity of the respective mutant (Chun, Finzi et al. 1995). 
Second, multi-infection of single cells in vivo is common and thus phenotypic 
mixing can contribute to mutant survival (Jung, Maier et al. 2002; 
Gelderblom, Vatakis et al. 2008). The recent suggestion that HIV is evolving 
towards a more robust population due to the selection of a lower fitness 
landscape is compatible with such a scenario (Arien, Vanham et al. 2007; 
Rolland, Brander et al. 2007). 
 
The development of drug resistance in HIV infection remains one of the most 
challenging difficulties in antiviral treatment. The dynamics of resistant 
mutants depends on a number of virus replication parameters such as the 
fitness values, the number of available target cells and 
mutation/recombination rates. Although the interplay between these factors 
has been studied using mathematical models, their results suffer from not 
being based on exact values for all parameters. Fitness is a major 
determinant in the selection process of drug-resistant mutants that is 
amenable to experimental quantification. In this respect, the fitness estimates 
for a complete spectrum of AZT-resistant mutants as a function of the drug 
concentrations obtained in this thesis work established a solid quantitative 
basis for further data-driven in silico studies. 
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In summary, this part of the study provides with high-resolution fitness values 
along an important HIV drug-resistance mutation pathway and quantifies the 
impact of epistasis on mutant frequencies. The pattern of epistatic 
interactions between the specific mutations was complex and dependent on 
environmental factors such as the presence and absence of drugs and the 
host cells used. While some interactions compensate fitness losses, the 
effect on the relative mutant frequencies was small so that epistasis as a 
buffering mechanism for fitness losses might be rather inefficient. The effect 
of epistasis on the mutant frequencies strongly depended on the change in 
the fitness ranking of individual variants upon incorporation of selective 
pressure and in the host cell environment. Taken together, the data 
presented in this work caution from over-interpreting qualitative data on 
epistasis for evolutionary dynamics of viruses without knowledge of the 
fitness ranking of the complete mutant spectrum. 
 
 
5.2 On the impact of phenotypic mixing in HIV 
One of the major consequences of single-cell multinfection in HIV is the 
generation of mixed viruses carrying viral features derived from different 
proviruses, a process called phenotypic mixing (Novick and Szilard 1951).  
Phenotypic mixing of viral products has been studied in many viruses (Lusso, 
di Marzo Veronese et al. 1990; Lusso, Lori et al. 1990; Rayner, Cordova et 
al. 1997; Wilke and Novella 2003). By altering the characteristics of a viral 
population (i.e. changes in cellular tropism, infectivity and fitness ), this 
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phenomenom might have a direct impact on vaccine effectiveness and 
antiviral therapy.  
 
For HIV, in vivo data show a proviral copy number of around 2 to 4 in single-
infected cells (Jung, Maier et al. 2002). This suggests that, besides 
recombination between different proviruses, phenotypic mixing of viral 
products might be common. In this thesis work, a thorough analysis of the 
fitness and infectivity of different phenotypically mixed HIV variants is 
presented. Fitness and infectivity of HIV-1 pseudotypes carrying an up to 1:4 
ratio of mixes of wild type and drug-resistant RTases and envelopes was 
experimentally quantified by infecting PBMC from different donors and under 
physiological concentrations of antiviral drugs ex vivo. The up to 1:4 ratio of 
mixing chosen for the experiments is in agreement with the estimated 
proviral copy number in infected cells, thus they capture a condition which is 
in the range of what could be expected in vivo.  Overall, the fitness and 
infectivity of the phenotypically mixed variants decreased gradually between 
the extreme phenotypes in a ratio-dependent manner (Figure 16).  Increasing 
drug concentrations rendered the extreme phenotypes more fit. 
 
An interesting exception was the observation that, without drug, the addition 
of 25% of the M41L mutant RTase inside the virions was sufficient to 
decrease by half the fitness of the original wild type phenotype (Figure 16). 
This initial decline in fitness was maintained among all in-between 
phenotypes carrying this mutant RTase and contrasted with the fitness 
behavior of the phenotypically variants carrying mixes of wild type and T215Y 
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or M41L-T21Y mutant RTases. This particular observation might be due to 
the combination of two main factors: i) the physical properties of the M41L 
mutation and ii) the RT copy number inside the virions. Structural studies 
suggest that an RT carrying the T215Y mutation alter the interactions 
between the RT and the template-primer resulting in a higher processivity 
than RT carrying the M41L residue, which is somewhat buried in the RT 
structure (Tantillo, Ding et al. 1994). Thus, viruses carrying a mix of wild type 
and T215Y RT might replicate more efficiently than viruses carrying only 
copies of the M41L RT. This is in agreement with a study by Julias et al. 
showing that, in virions phenotypically mixed with wild type RT and a 
catalytically inactive RT, a substantial decrease in replication took place 
when the virions contained around 50% catalytically active polymerase 
(Julias, Ferris et al. 2001), a similar behaviour as observed here with the 
M41L mutated RT. Second, it has been estimated that HIV carries around 50 
molecules of the RT inside a single virion (Stromberg, Hurley et al. 1974; 
Stromberg and Wilson 1974; Coffin 1979; Haseltine, Coffin et al. 1979). The 
reason for such high copy number is that the HIV-1 RT is a weak processive 
polymerase frequently dissociating from its primer-template. Even when a 
large number of RTase molecules may be required to complete viral DNA 
synthesis, it is not known if several RT molecules inside the reverse 
transcription complex compete for their recruitment to the template-primer. If 
that would be the case, it could be assumed that a competition between wild 
type and M41L RT for the template primer, plus the structural properties of 
the M41L RT, may be the reason of the fitness behavior observed in these 
phenotypically mixed variants. However this experiment has to be repeated. 
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Another situation was simulated in which a glycoprotein that is sensitive to 
the fusion inhibitor enfuvirtide (T20) (i.e. wild type envelope) and a T20-
resistant derivative were phenotypically expressed in an up to 1:4 ratio and 
used to infect PBMC under different concentration of T20.  With the 
exception of the variant carrying all copies of the T20-resistant envelope, T20 
gradually decreased the infectivity in a dose-dependent manner. In the range 
of the T20 IC50 for HIV-1 isolates using CCR5 as correceptor in vivo 
(Derdeyn, Decker et al. 2000), the IC50 for the fully sensitive pseudotype (i.e. 
the 100% wild type virus) in these cells was between 0.08 and 1µg/ml of T20 
for the fully sensitive variant (100% wild type) and 0.4µg/ml of T20 for the 
pseudotypes carrying 50% of resistant envelopes. The pseudovirions that 
contained both sensitive and resistant glycoproteins were only slightly less 
sensitive to enfuvirtide than the resistant pseudovirions under 2µg/ml of T20. 
Interestingly, the low infectivity (around 10%) exhibited by the fully resistant 
pseudotype (the 100% T20Res) without drug remained mostly constant until 
concentrations of 2µg/ml of T20. Under concentrations of 10µg/ml of the 
drug, the 100% wild type pseudotype was completely blocked and the 
infectivity of the 100%-T20Res was reduced by 50%. The infectivity of the 
intermediate variants was, as with the phenotypically mixed RT, in between 
the pure pseudotypes. 
 
The gradual decline in relative infectivity, (from the wild type through the in-
between variants), and the observation that pseudovirions containing 
different ratios of both sensitive and resistant glycoproteins were only slightly 
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less sensitive to enfuvirtide than the fully resistant, suggests that 
heterotrimers formed with wild type and T20-resistant glycoproteins are not 
completely blocked by enfuvirtide. This is in agreement with similar data 
obtained by Prof. Christian Jassoy (personal communication). However, 
these observations may be insufficient to make further assumptions on trimer 
function. For instance, it is yet not clear how many trimers HIV carries in its 
viral membrane, and how many are needed to succesfully infect a cell. The 
literature is inconclusive in this point.  
 
Infection of phenotypically mixed variants that are dual-resistant to AZT and 
T20 in combination, revealed some interesting features. First, without the 
addition of drugs, the intermediate variants carrying either resistant RTases 
or resistant envelopes in combination with the wild type showed a 
comparative mean relative fitness. This initially suggests that, in a drug-free 
environment, the inclusion of the wild type phenotype into the virion 
compensates equally to the fitness losses introduced by the mutant 
phenotypes. Second, upon addition of AZT and T20 in combination, the 
phenotypically mixed virions carrying the T20Res ENV exhibit higher relative 
fitness independent of the RT that it carried. Under 0.5 µM AZT and 0.5 
µg/ml T20, the difference in fitness favoring the WT RT-T20Res ENV over the 
T215Y RT-WT ENV phenotype was around 50%. Under the combination of 
AZT and T20, both resistance features (the ability to efficiently enter the cells 
and o reverse transcribe the genome) must contribute to the overall fitness. 
However, It appears that it is the virus ability to enter the cell by means of a 
resistant envelope rather than the RT that allows HIV to replicate more 
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efficiently under these conditions. To some extend, this observation may 
support the notion that, by means of phenotypic mixing, an otherwise 
detrimental feature (genotypic or phenotypic) might be useful for the virus in 
the face of a changing environment (Wilke and Novella 2003; Bellew and 
Chang 2006; Gelderblom, Vatakis et al. 2008).  
 
Despite the few exceptions highlighted above, the overall findings suggest 
that the incorporation of certain mutant products inside the virions does not 
change drastically the function of the resulting phenotype. This supports the 
notion that phenotypic mixing might contribute to the viral robustness in vivo. 
To further address this issue, the fitness and infectivity values generated 
from these experiments will be feed into a complete mathematical model of 
HIV evolution.  
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